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Protein folding is inherently dynamic and error prone. Even with an elaborate network of 
cellular factors, protein misfolding occurs frequently. To maintain protein homeostasis, 
eukaryotes have evolved a hierarchy of protein quality control checkpoints along the secretory 
pathway, including endoplasmic reticulum associated degradation (ERAD) and post-ER quality 
control (QC). Although most aberrant proteins are eliminated by ERAD, some misfolded 
proteins do exit the ER and are turned over by lysosomal proteases. To date, it remains elusive 
how misfolded membrane proteins are selected for different fates: ERAD versus post-ERQC. To 
address this question, a novel model substrate, SZ*, was designed and utilized in this study. SZ* 
is a single-pass membrane chimeric protein bearing cytosolic folding lesion. I first investigated 
its degradation fate in yeast and found that SZ* is eliminated by both the proteasome via the 
ERAD pathway and vacuolar proteases via the Golgi-QC pathway. The post-ER degradation of 
SZ* occurs after ER exit and requires the multivesicular body pathway. I then interrogated cells 
with different stress treatment to test how various conditions affect the fate of SZ*. My results 
showed that both heat-shock and substrate overexpression increase ERAD targeting, which both 
lead to substrate aggregation. Therefore, a misfolded membrane protein with a higher 
aggregation propensity is preferentially retained in the ER and targeted for ERAD. Next, I 
sequentially inhibited different steps in the ERAD pathway and tested SZ* ER export efficiency 
both in vivo and in vitro. I discovered that inhibiting steps required for ubiquitination, including 
substrate recognition and ubiquitination, facilitate ER exit of SZ* through coat protein complex 
 v 
(COP) II transport. These studies suggest that ERAD substrates can be rescued for ER export by 
eliminating ubiquitination. In line with this evidence, I fused SZ* to four tandem ubiquitin 
moieties that are not efficiently degraded by ERAD and found that this substrate could not exit 
the ER even when ERAD was inhibited. Together, these data provide evidence that substrate 
aggregation and ubiquitination can be sufficient for ER retention. 
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1.0  INTRODUCTION 
In eukaryotes, about one-third of the proteome is synthesized at the ER. These proteins 
first enter the ER through a protein translocon in an unfolded state (Rapoport et al., 2017). To 
gain functional activity and traffic to their final destinations, these proteins must fold into 
defined tertiary and in some cases quaternary structures. During the folding process, a myriad of 
chaperones are recruited to assist folding intermediates to overcome energy barriers before the 
energetically favorable conformation can be reached (Balchin et al., 2016). Protein folding in the 
ER is also guided by post-translational modifications, including glycosylation, disulfide bond 
formation, and lipidation (Braakman and Hebert, 2013). At this point, monomeric and multi-
subunit protein complexes can then continue their journey along the secretory pathway through 
COPII vesicle-mediated transport. 
Despite the enormous investment of cellular resources dedicated to protein folding, about 
12%-15% of newly synthesized polypeptides in human cells, and 1-5% in yeast are co-
translationally eliminated through ubiquitin-proteasome system (Duttler et al., 2013; Wang et al., 
2013). This percentage becomes even higher for post-translational protein degradation, as new 
proteins face even more challenges such as post-translational modifications, genetic mutations, 
defined metabolic states and environmental stress (Chen et al., 2011; Shao and Hegde, 2016; 
Trombetta and Parodi, 2003). In the cell, protein misfolding is toxic due to either loss-of-
function or gain-of-function activities. In one example, loss-of-function mutations can arise as a 
result of genetic mutation that makes the protein susceptible to degradation by one of several 
cellular quality control (QC) machineries.  Mutant variants of proteins such as the cystic fibrosis 
transmembrane conductance regulator (CFTR) and aquaporin 2 represent examples of disease-
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causing proteins that are trapped in the ER and are then efficiently disposed of by the 
endoplasmic reticulum-associated degradation (ERAD) pathway, which give rise to cystic 
fibrosis and alpha 1 antitrypsin deficiency, respectively (Guerriero and Brodsky, 2012; Stoller 
and Aboussouan, 2012; Veit et al., 2016). Other proteins, when mutated, can have detrimental 
gain-of-function effects by forming protein aggregates or polymers. These aggregation-prone 
proteins can engage in promiscuous interactions with other cellular components and accumulate 
in toxic cellular protein inclusions that sequester essential cellular components or organelles 
(Eisele et al., 2015). Proteins in the cytosol that exhibit this phenomenon include mutant 
Huntington protein  (Htt) and alpha-synuclein, which in turn lead to Hungtington’s disease and 
Parkinson’s disease, respectively (Sweeney et al., 2017). As the analysis of genomic and patient 
databases becomes more widespread, the number of conformational diseases that are related to 
protein misfolding and/or aggregation is growing (Guerriero and Brodsky, 2012; Tao and Conn, 
2018). 
To counteract protein misfolding and maintain protein homeostasis “proteostasis”, 
eukaryotes have evolved multiple QC mechanisms in the cytosol and along the secretory 
pathways, including cytoplasmic QC, ERAD, ER-phagy, Golgi QC (GQC) and plasma 
membrane QC (PMQC). For each of these processes, the unfolded protein response (UPR) and 
the heat shock response respectively serve as master regulators by adjusting protein synthesis, 
chaperone induction, and protein degradation pathways (Karagoz et al., 2019; Li et al., 2017; 
Preissler and Ron, 2018; Travers et al., 2000).  
ERAD clears most misfolded secretory proteins during or soon after proteins enter the 
ER by a step-wise mechanism: substrate recognition, retrotranslocation and ubiquitination, and 
proteasomal degradation (Berner et al., 2018; Hwang and Qi, 2018; Needham et al., 2019; 
 3 
Ruggiano et al., 2014; Vembar and Brodsky, 2008). The activity of ERAD needs to be tightly 
regulated as both hyperactive and hypoactive ERAD result in human disease (Guerriero and 
Brodsky, 2012; Hebert and Molinari, 2007). Notably, ER-phagy (see below) back-ups ERAD 
when folding is challenged by stress, or when protein aggregates/polymers arise in the ER that 
cannot be handled by the ERAD pathway. For example, alpha-1 antitrypsin deficiency is caused 
by degradation of mutant forms of alpha-1 antitrypsin (AT) in the ER, even though the protein 
retains residual function (Perlmutter, 2011). Interestingly, AAT with lower aggregation 
propensity or is present at lower levels are mostly degraded by ERAD, whereas accumulation of 
the most aggregation prone variant, AT-Z, is eliminated by ER-phagy (Fregno et al., 2018; Kruse 
et al., 2006; Teckman and Perlmutter, 1996; Teckman and Perlmutter, 2000). Nevertheless, some 
misfolded or unassembled proteins evade ERAD and ER-phagy, exit the ER, and become GQC 
substrates that are routed to the vacuole (in yeast) or lysosome (in higher cells) for degradation 
(Arvan et al., 2002). Of note, some native membrane proteins with polar residues in their 
transmembrane domain (TMD) mimic protein misfolding events and are recognized by a Golgi-
resident E3 ubiquitin ligase, Tul1, and sorted to the vacuole for maturation/degradation (Reggiori 
and Pelham, 2002). Compared to other substrates, GQC substrates may be less toxic so they can 
escape the ER and are recognized in the Golgi, which may operate with higher or perhaps altered 
specificity. Therefore, the ER acts as an initial triage center, selecting out the direst cases for 
ERAD/ER-phagy. In this chapter, I will review the mechanisms underlying ERAD, ER-phagy, 
and GQC, and highlight the “decisions” made in the ER to triage misfolded proteins for 




1.1  ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION 
ERAD is the primary defense mechanism in the ER to recognize and target terminally 
misfolded proteins for degradation. Initially, the ER was assumed to harbor the proteolytic 
activity for misfolded ER proteins (Needham and Brodsky, 2013). However, subsequent research 
revealed the cytosolic proteasome as the degradation machinery for misfolded ER proteins 
(Hampton et al., 1996; Hiller et al., 1996; Jensen et al., 1995; McCracken and Brodsky, 1996; 
Sommer and Jentsch, 1993; Ward et al., 1995; Werner et al., 1996). Therefore, the ER membrane 
establishes a physical barrier to separate the ER folding and degradation environments, 
protecting folding intermediates from premature degradation. The identification of ERAD 
components in multiple systems revealed an evolutionarily conserved process.  Despite the 
immense structural and topological diversity of proteins that enter the secretory pathway, work 
primarily in the budding yeast, S. cerevisae, revealed simple principles under which ERAD  
operates: misfolded ER proteins are recognized and ubiquitinated by one of three branches, 
ERAD-L (lumen), ERAD-C (cytoplasm) or ERAD-M (membrane), depending on the 
localization of the folding lesion relative to the ER membrane (Carvalho et al., 2006; Huyer et 
al., 2004b; Vashist and Ng, 2004). The key players required for substrate ubiquitination are the 
E3 ubiquitin ligases Hrd1 (ERAD-L/M) and Doa10 (ERAD-C). However, the assignment of 
mammalian ERAD substrates to three ERAD classes (ERAD-L/C/M) is less straightforward due 
to the existence of multiple E3 ligases that can work both individually and in concert with one 
another (Christianson and Ye, 2014). Therefore, I will mostly focus on studies in yeast. 
Nevertheless, common in both yeast and man are the critical early steps during ERAD, which 
include substrate recognition, retrotranslocation and ubiquitination, which in yeast differ between 
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each branch. Later steps during ERAD, including Cdc48/p97-mediated retrotranslocation and 
proteasomal degradation, are common to all three branches (Figure 1).   
1.1.1   ERAD-L 
To protect proteostasis, the ERAD-L machinery must recognize proteins that fail to 
acquire ER-specific post-translational modifications as well as terminally misfolded proteins 
with lesions within the ER. These latter substrates must be distinguished from folding 
intermediates that exhibit similar misfolded conformations. The requirement to monitor protein 
folding along with the acquisition of post-translational modifications makes ERAD-L unique and 
the most complicated of the three ERAD branches.  
The typical and best-characterized ERAD-L substrates are misfolded glycoproteins, as 
recognition requires both an N-linked glycan and protein determinants that are misfolded. During 
glycoprotein folding, a core glycan, Glc3Man9GlcNAc2, is first appended to an asparagine in the 
N-X-(S/T) consensus motif (Helenius and Aebi, 2004). This N-linked glycan is subsequently 
trimmed by a cascade of enzymes, which act in concert with chaperones and lectins to monitor 
glycoprotein folding. The three terminal glucose residues are cleaved sequentially by glucosidase 
I and II, generating Man9GlcNAc2 (Hitt and Wolf, 2004; Jakob et al., 1998). Further trimming 
by mannosidase I (Mns1) removes the α-1,2-mannose from the B-branch, yielding 
Man8GlcNAc2 (Camirand et al., 1991). This is the rate-limiting step during ERAD-L, which 
provides sufficient time to fold proteins that may be folding-competent (Jakob et al., 1998). 
Strikingly, Man8GlcNAc2 glycan is shared by both well-folded proteins exiting the ER and 
ERAD-L substrates, indicating that the Mns1 mannosidase does not discriminate between folded 
and misfolded proteins (Gauss et al., 2011). To instead generate an ERAD glycan signal, an 
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exposed α-1,6-mannose is generated by Htm1 (EDEM in mammals) in complex with protein 
disulfide isomerase Pdi1 (Gnann et al., 2004; Nishikawa et al., 2001). After the exposure of α-
1,6-mannose, misfolded glycoproteins are captured by the Yos9 (OS-9 and XTP-3B in 
mammals) lectins and molecular chaperones, which together deliver substrates to Hrd3 (Sel1 in 
mammals), a component of Hrd1 complex (Denic et al., 2006; Plemper et al., 1999; Xie et al., 
2009).  
Besides the ERAD glycan signal, another feature common in most terminally misfolded 
proteins and folding intermediates is exposed hydrophobic patches that are otherwise buried 
inside folded proteins. In addition to assisting in the delivery of substrates to Hrd3 (see above), 
these proteins are maintained in a soluble state by binding to ER-resident molecular chaperones, 
including the Hsp70 Kar2 (BiP in mammals) and Hsp40 partners Scj1 and Jem1 (Brodsky et al., 
1999; Gauss et al., 2011; Jakob et al., 1998; Nishikawa et al., 2001). 
Recent work suggests the involvement of another type of glycosylation event during 
ERAD, O-mannosylation of Ser/Thr residues by Pmt1/Pmt2 (Xu and Ng, 2015a; Xu and Ng, 
2015b; Xu et al., 2013). This modification is important to terminate futile folding cycles of 
certain misfolded lumenal protein and thus facilitate ERAD (Xu et al., 2013). Both N-glycan 
trimming and O-mannosylation are slow process, which lead to substrate lingering in the ER. In 
principle, this provides enough time for protein folding and re-folding, but on the other hand this 
potentially presents folding intermediates to the ERAD machinery since some chaperones are 
involved in both protein folding and turnover (Preston and Brodsky, 2017). This conundrum was 
recently solved by the discovery of a guardian complex, Slp1-Emp65, that plays an important 
role in protecting folding intermediates from premature degradation (Sun and Brodsky, 2017; 
Zhang et al., 2017).  
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After being selected, ERAD-L substrates are delivered to the Hrd1 complex, which 
includes Yos9, Hrd3, Der1, Usa1 and Hrd1. Since the Really Interesting New Gene (RING) 
domain in the Hrd ubiquitin ligase is localized on the cytosolic side of the ER membrane, soluble 
ERAD-L substrates need to be retrotranslocated or dislocated from the ER lumen to the cytosol 
to be modified. The identity of the proteinaceous “retrotranslocon” has been controversial.  
Sec61 and Hrd1 are currently the major candidates that function as the ERAD 
retrotranslocon. Because of its function as a protein-conducting channel for the ER, Sec61 was 
first suggested as the retrotranslocon during ERAD. Evidence supporting this hypothesis 
includes coimmunoprecipitation experiments demonstrating interaction between Sec61 and 
ERAD substrates as well as the proteasome (Kalies et al., 2005; Schafer and Wolf, 2009; Wiertz 
et al., 1996b). Some ERAD substrates, such as Apolipoprotein B, are retrotranslocated when 
translocation into the ER through Sec61 is interrupted, indicating that Sec61 has the potential to 
move proteins in either direction (Mitchell et al., 1998). Nevertheless, strong evidence 
implicating the Hrd1 ubiquitin ligase as the retrotranslocon has grown over recent years, at least 
for some substrates. First, the function of this 8 transmembrane protein during ERAD-L requires 
its oligomerization, which is mediated by Usa1, and Hrd1 interacts with substrates at an early 
retrotranslocation stage (Carvalho et al., 2010). Additional evidence for its activity as a 
retrotranslocation channel came from a recent in vitro reconstitution assay that recapitulated 
retrotranslocation with proteoliposomes containing both Hrd1 and an ERAD-L substrate. In the 
in vitro assay, an ERAD-L substrate tethered via a single transmembrane domain was poly-
ubiquitinated after addition of other components of the ubiquitin machinery outside the 
reconstituted vesicles. These data demonstrate substrate retrotranslocation across a lipid 
membrane (Baldridge and Rapoport, 2016). The identity of Hrd1 as a retrotranslocon was further 
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corroborated by a recent cryo-electron microscopy (cryo-EM) structure of Hrd1 in complex with 
Hrd3 (Schoebel et al., 2017). In the structure, Hrd1 forms a dimer within the membrane with 
Hrd3, which is associated on the lumenal side of the ER membrane.  Five of eight 
transmembrane segments of Hrd1 form a funnel that extends from the cytosol almost to the 
lumenal side of the membrane. In addition, the aqueous cavity formed by Hrd1 is reminiscent of 
that formed by Sec61.  
Another early candidate for the retrotranslocon was Der1, which is a multi-spanning 
membrane protein that is also required for elimination of ERAD-L substrates (Knop et al., 1996; 
Mehnert et al., 2014; Vashist and Ng, 2004). As a component of the Hrd1 complex, Der1 
receives ERAD-L substrates from the recognition factors Yos9/Hrd3 and transfers them to the 
Hrd1 ligase through the Hrd1 scaffold protein Usa1 (Horn et al., 2009; Mehnert et al., 2014). In 
one study, Der1 (Derlin-1 in mammals) was shown to directly facilitate the retrotranslocation of 
mutant pro-α-factor in vitro using mammalian microsomes loaded with the substrate (Wahlman 
et al., 2007). Mutant pro-α-factor is a non-canonical substrate whose degradation is ubiquitin-
independent, potentially bypassing the requirement of Hrd1 as both an E3 ligase and 
retrotranslocon (Werner et al., 1996). Therefore, Der1 may act both as a mediator to recruit 
ERAD-L substrates to the membranous Hrd1 complex and as retrotranslocon for non-
ubiquitinated ERAD substrates, like pro-α-factor and possibly cholera toxin (Kothe et al., 2005). 
More recent evidence indicated that Der1 intimately contacts ERAD substrates as they exit the 
ER, and it was proposed to facilitate the solubilization of membrane proteins, which could 
increase access to Hrd1 (Mehnert et al., 2014). Overall, several integral membrane components 
in the ER remain as strong candidates as the retrotranslocon for ERAD-L substrates. 
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1.1.2  ERAD-M 
ER membrane proteins with folding lesions within transmembrane domains are 
recognized and eliminated by ERAD-M, in which the Hrd1 complex plays a major role. In 
contrast to recognition of ERAD-L substrates, the identification of folding lesions within the 
lipid bilayer is especially challenging as these lesions not be accessible to any known chaperone. 
In fact, the composition of the Hrd1 complex for ERAD-M—only Hrd1 and Hrd3—is 
significantly simpler than the Hrd1 complex for ERAD-L.  
HMG-CoA reductase (Hmg2 in yeast and HMGR in mammals) is the best-characterized 
ERAD-M substrate, which in fact led to the identification of Hrd1 (HMG-CoA reductase 
degradation) (Hampton et al., 1996). During sterol biosynthesis, this enzyme is the rate-limiting 
step and thus HMG-CoA reductase stability undergoes stringent regulation in response to cellular 
sterol levels (Wangeline et al., 2017). When sterol levels are low, Hmg2 is stabilized by a sterol-
dependent chaperone, the insulin-induced gene proteins (INSIGs). When sterol levels are high, 
Hmg2 appears to adopt a conformation that is recognized by the ERAD-M machinery and is 
rapidly degraded by ERAD (Theesfeld and Hampton, 2013). Unlike ERAD-L substrates, ERAD-
M substrates such as Hmg2, Sec61-2, and Pdr5* appear to be directly recognized by the Hrd1 
ubiquitin ligase via the transmembrane domain (Sato et al., 2009). Specifically, site-directed 
mutagenesis supported the view that Hrd1 recognizes misfolded lesions in transmembrane 
domain. Because ERAD-M substrates are already anchored in the ER membrane, they may 
directly enter the Hrd1 retrotranslocon sideways from the lipid bilayer for retrotranslocation and 
coupled ubiquitination.  
Recently, the ERAD-C ubiquitin ligase, Doa10 (see below), was also shown to be 
involved in the turnover of a specific ERAD-M substrate: the unassembled Sec61β homologue 2 
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(Sbh2), which presents an exposed transmembrane degron (Habeck et al., 2015). In addition, 
some ERAD-M substrates, like Sec61-2, can mislocalize to the inner nuclear membrane, a 
specialized ER subdomain, and are instead recognized by the Asi complex for proteasomal 
degradation. During this process, the Asi complex seems to recognize folding lesions within the 
transmembrane domain, similarly to Hrd1 (Foresti et al., 2014; Khmelinskii et al., 2014).  Yet 
another class of non-canonical ERAD-M substrates are single-pass membrane proteins, such as 
unassembled α, β T-cell receptor subunits, whose transmembrane domains are less hydrophobic. 
These subunits can completely enter the ER lumen before retrotranslocation, and are recognized 
by the ER lumenal Hsp70 (BiP) for ERAD (Feige and Hendershot, 2013). Therefore, ERAD-M 
substrates with different types of folding lesions may employ diverse mechanisms for 
recognition prior to the proteasomal degradation.  
1.1.3   ERAD-C 
ERAD-C deals with misfolded membrane proteins with folding lesions located in their 
cytosolic domain, which requires a different set of chaperones and E3 ubiquitin ligases compared 
to ERAD-L substrates. The common feature of ERAD-C substrates is the exposure of 
hydrophobic patches that are otherwise buried inside the native conformation. To prevent protein 
aggregation, cytosolic chaperones including cytoplasmic isoforms of Hsp70 (Ssa1-4 in yeast), 
Hsp40 (Ydj1 and Hlj1 in yeast), nucleotide exchange factors (NEFs), Hsp90, and small heat 
shock proteins (sHsps) are engaged for efficient clearance of ERAD-C substrates (Ahner et al., 
2007; Huyer et al., 2004b; Park et al., 2007; Youker et al., 2004).  Hsp70 captures hydrophobic 
patches exposed in folding intermediates and ERAD-C substrates to sequester them from the 
aqueous environment, thereby preventing protein aggregation and assisting protein folding 
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(Vembar and Brodsky, 2008). In turn, the peptide binding and release cycle of Hsp70 is 
intrinsically slow and is regulated by both the Hsp40 co-chaperone and dedicated NEFs. In terms 
of ERAD-C substrates that are terminally misfolded, futile folding cycles must be prevented so 
the substrate can be targeted for degradation. Chaperones including Hsp70 (Ssa1) and Hsp40 
(Ydj1 and Hlj1) have been shown as recognition factors for a growing number of ERAD-C 
substrate in yeast, such as CFTR, Pma1-D378S, Ste6*, Chimera A*, and SZ* (Guerriero et al., 
2017; Han et al., 2007; Huyer et al., 2004b; Sun and Brodsky, 2017; Youker et al., 2004). 
Moreover, an in vitro ubiquitination system was used to show that Hsp70 (Ssa1) and Hsp40 
(Ydj1 and Hlj1) are required for both substrate recognition and E3 ubiquitin ligase recruitment 
(Nakatsukasa et al., 2008).  Although it is not understood how the same set of chaperones dictate 
proteins to different fates (i.e., folding versus degradation), prolonged chaperone engagement 
might provide enough time for recruitment of the E3 ubiquitin ligase, Doa10, to tag ERAD-C 
substrates with a poly-ubiquitin chain.  
Unlike ERAD-L substrates that undergo retrotranslocation-coupled ubiquitination, 
ERAD-C substrates are ubiquitinated prior to retrotranslocation because their cytosolic domains 
gain easy access to the cytosolic RING domain in Doa10. During ubiquitination, a cascade of 
ubiquitin enzymes, including the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating 
enzyme, and an E3 ubiquitin ligase are required to deliver the ubiquitin moiety to the substrates 
(Oh et al., 2018). For ubiquitination of ERAD-C substrates, two E2 ubiquitin-conjugation 
enzymes, Ubc6 and Ubc7, are involved. Recently, it was shown that Ubc6 can attach a single 
ubiquitin not only to lysine residue but also to hydroxylated amino acids, which can act as 
primers for subsequent poly-ubiquitination by Ubc7, thus expanding the substrate range of 
Doa10 (Weber et al., 2016). In addition to Doa10, another cytosolic/nuclear E3 ligase 
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responsible for N-end rule degradation, Ubr1, also contributes to the turnover of ERAD-C 
substrates, like Ste6* and CFTR in yeast (Prasad et al., 2018; Stolz et al., 2013). Because 
polytopic membrane proteins may bear multiple folding lesions, different branches of ERAD 
may also coordinate with each other during substrates recognition and ubiquitination for efficient 
clearance of misfolded proteins in the ER.  
1.1.4   Protein Retrotranslocation and Proteasomal Degradation 
Following substrate ubiquitination or retrotranslocation-coupled ubiquitination, all three 
ERAD branches converge on the Cdc48/p97-mediated retrotranslocation step, during which 
ubiquitinated ERAD substrates are extracted from the ER/the ER membrane and are transferred 
to the 26S proteasome. After being marked with a poly-ubiquitination chain, ERAD substrates 
recruit the cytosolic Cdc48 (p97 in mammals) complex by interacting with the ubiquitin-
interacting Cdc48 cofactors Ufd1/Npl4 (Braun et al., 2002; Jarosch et al., 2002; Ye et al., 2003). 
The recruitment of the Cdc48 complex is further facilitated by an ER integral membrane protein, 
Ubx2, which also interacts with Ufd1/Npl4 (Neuber et al., 2005; Schuberth and Buchberger, 
2005). The Cdc48 complex next provides the driving force for retrotranslocation via ATP 
hydrolysis and “pulls” ubiquitinated substrates out of the ER membrane and into the cytosol 
prior to proteasomal degradation (Ye et al., 2003).  
Cdc48 is a member of the ATPases Associated with various cellular Activities (AAA+ 
ATPase) family, which use ATP hydrolysis to exert force on macromolecules (Snider et al., 
2008). Members of this family form hexamers with two stacked ATPases rings (D1 and D2) 
surrounding a central pore, which is reminiscent of the protein unfolding/disaggregating channel 
Hsp104 (Gates et al., 2017) as well as a bacterial disaggregase, ClpB (Mogk et al., 2015). 
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Although it has long been known that Cdc48 extracts proteins from the ER membrane during 
ERAD, a more detailed mechanism of substrate processing by Cdc48 was recently revealed by 
an in vitro reconstitution system (Blythe et al., 2017; Bodnar and Rapoport, 2017). During 
retrotranslocation, a substrate bearing a K48 linked poly-ubiquitin chain first binds to Ufd1/Npl4, 
and is locally denatured in the D1 ring in the Cdc48 complex. The unfolded loop of the substrate 
reaches to the central pore of the Cdc48 complex, and as it travels further into the pore it is 
pulled by pore loops in the D2 ring upon ATP hydrolysis. During entry, the binding of poly-
ubiquitinated substrates by Ufd1/Npl4 is weakened or diminished by the trimming of a poly-
ubiquitin chain on the substrate, thus releasing the substrate and facilitating further threading 
through the central pore of Cdc48. The trimming of poly-ubiquitin chains is mediated by a 
deubiquitinase (DUB), which generates heterologous retrotranslocated substrates with different 
ubiquitin chain lengths. At this stage, substrates with ubiquitin chains that are too short to be 
degraded by the proteasome will be rescued by the Cdc48 cofactor Ufd2, an E4 ubiquitin 
elongation enzyme (Koegl et al., 1999). For ERAD-L substrates bearing N-linked glycans, 
another Cdc48 binding partners, Png1, may remove the carbohydrates before proteasome 
delivery. Of note, Png1 binds to C-terminus of Cdc48 and probably functions only on unfolded 
substrates after their translocation (Li et al., 2006). 
After being retrotranslocated from the ER, ERAD substrates are then delivered to the 
proteasome for degradation, which is facilitated by the shuttling factors Rad23 and Dsk2 and that 
contain both ubiquitin- and proteasome-binding domains (Kim et al., 2004; Medicherla et al., 
2004). In higher eukaryotes, a chaperone holdase complex, including Bag6, Ubl4A, and Trc35, 
associates with retrotranslocated ERAD substrates to prevent their aggregation and facilitate 
degradation (Wang et al., 2011b). The engagement of chaperone holdases is rather important for 
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retrotranslcoated membrane proteins such as those in ERAD-C substrates, which contain 
hydrophobic transmembrane domains and are thus aggregation prone in the cytoplasm. However, 
Bag6 lacks a yeast ortholog. The best candidate for this holdase in yeast is Hsp104, which was 
recently shown to facilitate the retrotranslocation of insoluble ERAD substrate via its ATPase 
activity (Preston et al., 2018). It is also possible that retrotranslocated membrane substrates 
undergo an autonomous conformational change to bury aggregation prone domains without the 
need of a holdase chaperone.   
1.1.5  Protein Quality Control versus Quantity Control by ERAD 
Besides misfolded or damaged proteins, normal proteins that are deemed unnecessary are 
also turned over by ERAD, which is termed quantity control. In order for quantity control 
substrates to be recognized by ERAD, they have to display signals that mimic misfolded proteins 
in response to a cellular signal or the presence of an adaptor.  
During sterol biosynthesis, Hmg2 (see above) is susceptible to ERAD-M in response to 
the accumulation of a pathway intermediate, isoprene geranylgeranyl pyrophosphate (GGPP) 
(Wangeline et al., 2017). On the contrary, low lipid levels serve as a signal for quantity control 
of ApoB: ApoB that fails to become lipidated misfolds and is eliminated by ERAD (Doonan et 
al., 2018). Some transporters are also regulated by ERAD quantity control by ligand binding.  
The cadmium exporter, Pca1, contains a cytosolic degron that targets Pca1 for ERAD in the 
absence of cadmium. When cellular cadmium levels are high, Pca1, is stabilized and escapes 
ERAD to act rapidly in response to cadmium (Adle et al., 2009). Therefore, cells employ ERAD 
quantity control to selectively degraded unnecessary proteins to save energy and building blocks 
to synthesize other proteins.  
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In contrast to metabolic regulation of ERAD quantity control, adaptor protein-mediated 
quantity control is also prevalent. For example, a yeast ER intramembrane protease, Ypf1, was 
identified as an adaptor to mediate ERAD of a zinc transporter, Zrt1, under zinc replete condition 
(Avci et al., 2014). Clipping of Zrt1 by Ypf1 introduces a misfolding signal that recruits Dfm1 (a 
Der1 homolog) and Doa10, thus targeting Zrt1 for ERAD. Another example of adaptor-mediated 
quantity control occurs when ERAD is hijacked by a virus. The human cytomegalovirus (CMV) 
encodes membrane adaptor proteins US2 and US11, which independently bind to newly 
synthesized major histocompatibility class I (MHC-1) molecules and recruit the ERAD 
machinery (Loureiro et al., 2006; Stagg et al., 2009; Wiertz et al., 1996a). Surface display of 
MHC-1 is reduced, thereby disabling the host immune response. A similar strategy is used by the 
HIV-encoded adaptor protein Vpu, which targets human CD4 for ERAD (Fujita et al., 1997; 
Schubert et al., 1998).  
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Figure 1 Three branches of ERAD pathway in yeast 
Lower panel defines the different steps in substrate recognition and ubiquitination for ERAD-L/M/C 
substrates. ERAD-L substrates containing lumenal folding lesion (red star) and N-linked glycan (grey 
diamond) are recognized and processed by a cascade of enzymes to generate ERAD glycan signal (red 
diamond). Chaperones (Kar2) and lectins (Yos9) then capture the ERAD-L substrates and transfer it to 
the Hrd1 complex for retrotranslocation coupled ubiquitination (red triangle). ERAD-M substrates 
containing a membranous folding lesion (red star) are directly recognized and ubiquitinated by Hrd1 
complex. ERAD-C substrates containing cytosolic folding lesion are recognized by cytosolic chaperones 
(eg. Ydj1 and Ssa1), which then bridge the interaction between ubiquitin ligase Doa10 and substrates for 
ubiquitination. All three ERAD branches converge in the retrotranslocation step mediated by Cdc48 
complex including Cdc48 and its cofactor Ufd1 and Npl4 that interact with ubiquitin (red triangle) on 
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substrates (upper panel). Cdc48 provides the molecular force via ATP hydrolysis to extract substrates 
from the ER to the cytosol. Following retrotranslocation, substrates are escorted to the 26S proteasome 
for degradation by shuttling factors Rad23 and Dsk2.  
 
1.2  ER-PHAGY 
The diameter of the pore of the ERAD retrotranslocon may prevent misfolded oligomeric 
or aggregated proteins, or proteins that are only partially unfolded, from being retrotranslocated.  
Because these substrates may become even more toxic as they accumulate, the ER is equipped 
with a backup QC mechanism to clear misfolded proteins that cannot be disposed of by ERAD, 
ER-phagy. Like other autophagy pathways, ER-phagy can exhibit selectivity to discriminate 
between functional proteins and damaged non-functional proteins, as well as act as a 
nonselective pathway to eliminate bulky ER materials that accumulate upon ER stress. ER-phagy 
can be classified into micro-ER-phagy (non-selective) and macro-ER-phagy (selective) 
(Lipatova and Segev, 2015). 
1.2.1   Micro-ER-phagy 
The term “ER-phagy” was firstly used by the Walter group upon the discovery of ER 
whorls (Bernales et al., 2006; Bernales et al., 2007). Treatment with dithiothreitol (DTT) and 
tunicamycin, which disrupt protein disulfide bond formation and glycosylation in the ER lumen, 
respectively, and induce the unfolded protein response (UPR), results in massive ER expansion 
 18 
followed by the formation of the whorls. The ER whorls are then selectively engulfed into the 
vacuole by invagination and inward budding of the vacuolar membrane, which occurs 
independently of the core autophagy machinery. This is reminiscent of the process of 
microautophagy. However, micro-ER-phagy differs from microautophagy in the fact that none of 
the microautophagy-related components, including the EGO complex, the vacuolar transporter 
chaperone complex (VTC) and the endosomal sorting complexes required for transport (ESCRT) 
(see below), is required for micro-ER-phagy (Dubouloz et al., 2005; Sahu et al., 2011; 
Uttenweiler et al., 2007). The trigger for micro-ER-phagy seems instead to be ER expansion 
rather than the accumulation of misfolded proteins in the ER, because expansion of the ER by 
directly knocking out OPI1, the lipid biosynthesis transcriptional repressor, is sufficient to 
induce micro-ER-phagy (Schuck et al., 2014; Schuck et al., 2009). Therefore, micro-ER-phagy 
may remove ER subdomains in the vacuole to re-establish pre-stress ER volume and content. 
Thus far, this phenomenon has only been reported in yeast.  It also remains largely illusive how 
ER expansion triggers micro-ER-phagy, and if a receptor is required during this process.  
1.2.2  Macro-ER-phagy 
Compared to micro-ER-phagy, macro-ER-phagy is a conserved mechanism which is 
induced in response to cellular stress induced by nitrogen starvation, rapamycin treatment, and 
protein aggregation in the ER (Grumati et al., 2018). Also in contrast to micro-ER-phagy, macro-
ER-phagy coopts the autophagy core machineries. The discovery of various ER-phagy receptors 
also indicates that macro-ER-phagy is a highly selective and regulated mechanism that helps 
maintain ER homeostasis.  
 19 
In budding yeast, macro-ER-phagy is induced by nitrogen starvation and rapamycin 
treatment, during which two ER-phagy receptors are required (Mochida et al., 2015). Atg39 
localizes to the perinuclear ER and induces ER-phagy of a nuclear subdomain. Atg40 mainly 
localizes to the cortical and cytoplasmic ER and instead mediates the autophagic sequestration of 
ER subdomains. Both Atg39 and Atg40 contain an Atg8 family interacting motif, which engages 
Atg8 on the phagophore membrane (the precursor of the autophagosome).  In addition, another 
autophagosome scaffold protein, Atg11, which recruits the autophagosome-formation machinery 
onto the receptor-target complex, binds both Atg39 and Atg40 (Mochida et al., 2015; Okamoto, 
2014). Of note, nitrogen starvation or rapamycin treatment enhances the expression of both 
Atg39 and Atg40, which forms a feedback loop to regulate nitrogen starvation or rapamycin-
induced ER-phagy. Overexpression of a membrane protein, Snc1, can also trigger macro-ER-
phagy, during which autophagy related genes including Atg1, atg8, atg9 and a small GTPase 
Ypt1 are required (Lipatova and Segev, 2015). Overexpression of Snc1 results in its 
sequestration first into ER-to-autophagy membranes (ERAM), and Ypt1-dependent recruitment 
of select proteins to ERAM forms the autophagosome, which fuse with the lysosome. ATZ 
expressed in yeast undergoes both ERAD (see above) as well as autophagy-dependent 
degradation, indicating the potential for protein-mediated ER-phagy in yeast (Kruse et al., 2006). 
In mammalian cells, ATZ is sorted into an autophagosome for ER-phagy by the ER-phagy 
receptor FAM134B (Fregno et al., 2018). In contrast, the yeast ER-phagy receptors for either 
overexpressed Snc1 or ATZ remain enigmatic.  
In mammalian cells, macro-ER-phagy is induced by nutrient deprivation, accumulation of 
misfolded and/or aggregated proteins, and some pathogens (Dikic, 2018; Grumati et al., 2018; 
Loi et al., 2018). ER-phagy also provides a backup mechanism for ERAD to dispose of ERAD-
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resistant misfolded proteins, such as intracisternal granules (ICGs), mutant dysferlin, 
procollagen, ATZ, and a gonadotropin-releasing hormone receptor mutant (Fujita et al., 2007; 
Hidvegi et al., 2010; Houck et al., 2014; Ishida et al., 2009; Kruse et al., 2006; Tooze et al., 
1990).  
The identification of ER-phagy receptors, including FAM134B, RTN3, Sec62, and 
CCPG1, has greatly advanced our understanding of macro-ER-phagy in mammalian cells and 
expanded its function to both counteract cellular stress and re-establish ER volume and content 
after stress (Fumagalli et al., 2016; Grumati et al., 2017; Khaminets et al., 2015; Smith et al., 
2018). The first characterized receptor, FAM134B, mediates starvation-induced ER-phagy in 
mammalian cells (Khaminets et al., 2015). It localizes at the edge of ER sheets via a reticulon 
homology domain (RHD), which can promote curvature of the ER membranes during 
autophagosome formation. The presence of a LIR at the cytosolic C-terminus confers upon 
FAM134B the ability to recruit LC3 and/or GABARAP at the limiting membrane of growing 
phagophores. Both the RHD and LIR of FAM134B are required to complete ER-phagy. 
Downregulation of the gene encoding FAM134b leads to ER expansion as a result of defective 
ER-phagy under both basal and starvation conditions. In contrast, overexpression results in ER 
fragmentation and lysosomal degradation. These data position FAM134B as a regulator of ER 
size under basal and stressed conditions.   
After the identification of FAM134B, an increasing number of misfolded proteins have 
been identified as cargo. For example, collagen is the main structural component of the 
extracellular matrix, and ~20% of newly synthesized type I procollagens (PC1) is degraded in 
the lysosome due to inefficient PC1 folding (Bienkowski et al., 1986; Ishida et al., 2009). 
Collagen mutants are associated with several matrix-associated diseases, including osteogenesis 
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imperfecta (Marini et al., 2007). Mutations in PC1 or the Hsp47 collagen chaperone form 
ERAD-resistant protein aggregates, which are eliminated by ER-phagy in an FAM134B-
dependent manner (Forrester et al., 2019; Fregno et al., 2018; Ishida et al., 2006).  Moreover, an 
ERAD-L component, calnexin, was found as a co-receptor that recognizes misfolded PC1 in the 
ER and interacts with FAM134B, linking ERAD and selective ER-phagy. Since FAM134B lacks 
domains that reside in the ER lumen, it makes sense that ER-phagy employs ERAD-L 
components to recognize and dispose of misfolded proteins in the ER lumen.   
Recently, another FAM134B substrate was identified as a misfolded transmembrane 
glycoprotein, I1061T NPC1 (Schultz et al., 2018). Unlike other ER-phagy substrates that are 
ERAD-resistant, I1061T NPC1 can be degraded by both ERAD and ER-phagy (Gelsthorpe et al., 
2008; Schultz et al., 2018). Because the components involved in the ERAD of I1061T NPC1 are 
not well characterized, the misfolded lesion in I1061T NPC1 either transmits this conformational 
change to its membrane or cytosolic domain or engages other ERAD-L components, like 
calnexin, to recruit FAM134B.  
Several other ER-phagy receptors and facilitators of ER-phagy also exist. For example, 
RTN3 is an RHD-containing protein that has the potential to induce membrane curvature and 
thus localizes at ER tubules (Yang and Strittmatter, 2007). RTN3 exists in various splicing 
isoforms, but only the longest one carries LIR domains and functions as an ER-phagy receptor 
(Grumati et al., 2017). Under amino acid starvation condition, RTN3 oligomerizes to engage and 
cluster LC3 to form autophagosomes from ER tubules for lysosome delivery and degradation 
(Grumati et al., 2017). In addition, Sec62 was recently discovered as a receptor for “recovER-
phagy” that is independent of its function during protein translocation (Fumagalli et al., 2016). 
During the UPR, eukaryotes expand their ER to protect protein homeostasis. Unlike yeast that 
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utilize micro-ER-phagy to regulate the shape and size of the ER during ER stress (see above), 
mammalian cells activate recovER-phagy as ER stress is resolved and to reset ER volume and 
content. Through the C-terminal LIR domain, mammalian Sec62 acts as the receptor for 
recovER-phagy. Compared to the mammalian homolog, Sec62 in yeast lacks a putative LC3-
interacting region (LIR), based on which I speculate that the loss of LIR on yeast Sec62 may 
explain the dispensability of autophagy core machineries during micro-ER-phagy. It is unclear if 
yeast lost the LIR domain or whether this domain was gained during evolution as diverse 
mechanisms for ER-phagy evolved.  
Similar to Sec62, Cell-Cycle Progression Gene 1 (CCPG1) is another ER-phagy receptor 
associated with the UPR (Smith et al., 2018).  CCPG1 contains both LIR and FIP200-interacting 
regions, which bind independently to LC3 as well as FIP200, a component that associates with 
the autophagy machinery. During ER stress, CCPG1 expression is upregulated to remove 
portions of the ER harboring insoluble proteins. ER-phagy mediated by CCPG1 plays an 
important role in protecting pancreatic acinar cells against protein aggregation in the ER lumen 
and subsequent UPR induction (Smith et al., 2018). However, it is still unknown how CCPG1 
recognizes and clusters aggregated proteins for ER-phagy. Because of its large ER lumenal 
domain, CCPG1 may either work on its own or with ERAD-L components to recognize its 
substrates. Overall, even though the identification of these ER-phagy receptors has helped define 
how cargos are selected, how the ER-phagy machinery “decides” where and when to degrade a 
misfolded protein is an important future undertaking. 
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1.3  GOLGI QUALITY CONTROL 
Folded and mature proteins in the ER travel along the secretory pathway to the Golgi via 
COPII vesicle transport. The COPII coat consist of five subunits: Sar1, Sec23/24 dimer, and 
Sec13/31 tetramer (Barlowe et al., 1994). In brief, the formation of COPII vesicles is initiated by 
activating the small GTPase Sar1 upon association with a guanine nucleotide exchange factor 
(GEF), Sec12. Activation induces a conformational change in Sar1 (Sar1-GTP), exposing 
hydrophobic elements that insert into the ER membrane. A Sec23/24 heterodimer is then 
recruited to the ER by Sar1-GTP to form the inner COPII coat, to which the outer coat formed by 
the Sec13/31 heterotetramer, is recruited via direct interaction between Sec31 and Sec23/Sar1. 
The formation of this coat complex then stimulates the GTPase activating activity of Sec23 to 
promote Sar1 GTP hydrolysis, thus switching Sar1 back to the inactive state (Barlowe and 
Helenius, 2016). During this process, transport-competent cargo transiently accumulate or 
concentrate at specialized ER subdomains called ER exit sites (ERES) (Lee et al., 2004). Due to 
the size limit of COPII vesicles (usually less than 90 nm in diameter), the packaging of large 
cargos like procollagen and apolipoproteins requires expansion of COPII by the formation of 
large vesicles or a tunnel between the ER and the ER-Golgi intermediate compartment 
(ERGIC)/Golgi (Jin et al., 2012; McCaughey et al., 2019; Raote and Malhotra, 2019; Raote et 
al., 2018). Recently, a novel mechanism termed autoregulation of ER export (AREX) has been 
discovered in human cells that monitors and regulates the secretory flux of folded cargos in the 
ER through COPII (Subramanian et al., 2019). In response to an elevated amount of folded 
secretory cargos, AREX components are activated to both facilitate cargo export and attenuate 
protein synthesis, thus preventing the accumulation of folded and potentially harmful cargo in 
the ER (Subramanian et al., 2019). As the next station in the protein secretory pathway, the Golgi 
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apparatus not only functions as a protein post-translational modification factory--adding 
modifications such as glycosylation, acetylation, phosphorylation, sulfation, palmitoylation, 
methylation, and proteolytic cleavage--but also as a QC step to protect protein homeostasis along 
the secretory pathway (Arvan et al., 2002; Potelle et al., 2015).  
A growing number of misfolded proteins have been identified that escape ERAD and are 
delivered to the vacuole/lysosome for degradation after selection in the Golgi. These data 
suggested the existence of a quality control mechanism in this compartment. Surprisingly, some 
misfolded proteins entering the Golgi can also be targeted for proteasomal degradation after 
delivery back to the ER. Thus, based on where they are targeted for degradation, GQC can be 
divided into proteasome-targeted GQC and lysosome/vacuole-targeted GQC (Figure 2).  
1.3.1   Proteasome-targeted GQC 
Some misfolded proteins can escape ERAD and ER-phagy and can be packaged into 
COPII vesicles for anterograde trafficking to the Golgi (Caldwell et al., 2001; Taxis et al., 2002; 
Vashist and Ng, 2004). Proteasome-targeted GQC captures the escaped substrates most likely in 
the cis-Golgi and cycles them back to the ER for ERAD. A fully competent ER to Golgi 
trafficking pathway, therefore, is required for efficient ERAD of some misfolded proteins.  
Evidence from both yeast and mammalian studies support the involvement of the Golgi 
during ERAD. In budding yeast, efficient elimination of some ERAD-L substrates (CPY*, PrA*, 
KHN and KWW) requires a functional early secretory pathway (Caldwell et al., 2001; Taxis et 
al., 2002; Vashist et al., 2001; Vashist and Ng, 2004), and blocking anterograde trafficking 
inhibited ERAD-L. Erv29, which cycles between ER and Golgi, was identified as the COPII 
vesicle cargo receptor for CPY* and PrA* (Caldwell et al., 2001; Vashist et al., 2001). As 
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anticipated, COPI vesicle transport, which mediates retrograde trafficking from the Golgi to the 
ER, was involved in efficient degradation of CPY* and KHN (Vashist et al., 2001).  In addition 
to ERAD-L substrates, some misfolded proteins with mutated transmembrane domains were also 
retrieved from the Golgi to the ER via a known retrieval receptor, Rer1 (Letourneur and Cosson, 
1998). Because both Erv29 and Rer1 are general receptors that do not distinguish between 
misfolded and normal cargos, the escaped ERAD substrates are probably packaged into COPII 
and retrieved via COPI vesicles along with proteins that normally reside in the ER. 
In mammals, unassembled MHC class I proteins expose polar residues in the 
transmembrane domain that are otherwise shielded by a partner protein, which leads to ERAD 
(Hughes et al., 1997). However, instead of being retained in the ER, unassembled MHC class I 
molecules advance to the cis-Golgi before retrieval back to the ER (Hsu et al., 1991). A similar 
result was also shown for the MHC class II β subunit, which can cycle between the Golgi and 
ER. The accelerated proteasomal degradation of β subunit upon brefeldin A treatment, is 
consistent with Golgi cycling during ERAD (Dusseljee et al., 1998). Consistent with findings in 
yeast, COPI vesicle transport also plays an important role in cycling an unassembled TCR α 
chain back to the ER (Yamamoto et al., 2001). Moreover, the ER chaperone BiP and the HDEL 
receptor helped retrieve proteins, such as a vesicular stomatitis virus G protein (VSVG) mutant 
and an unassembled TCR α chain (Hammond and Helenius, 1994; Yamamoto et al., 2001). 
Consistent with data in yeast, the human ortholog of Rer1 was also involved in the Golgi 
retrieval process for misfolded proteins with lesions in a transmembrane domain, such as the 
G51R rhodopsin mutant and a chimeric protein, CD8TMD* (Briant et al., 2017; Yamasaki et al., 
2014).  
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Regardless of the mechanism by which substrates are retrieved, the ERGIC and cis-Golgi 
seem to be the location where GQC occurs due to the following reasons. First, all currently 
identified retrieval receptors, including the HDEL receptor, Rer1, and Erv29, are primarily 
localized in the cis-Golgi under steady-state conditions. Second, proteasome-targeted GQC 
substrates, such as N153D tissue-non-specific alkaline phosphatase (TNSALP), MHC class I 
molecules, and MHC class II β subunit, fail to acquire Golgi modifications, which happens in the 
medial-Golgi in mammalian cells, as indicated by sensitivity to Endo H cleavage (Dusseljee et 
al., 1998; Hsu et al., 1991; Ito et al., 2002). Thus, proteasome-targeted GQC may act as the first 
barrier to prevent escaped ERAD substrates from entering steps in the secretory pathway beyond 
the cis-Golgi. Notably, knockdown of mammalian Rer1 resulted in transport of the G51R 
rhodopsin mutant and the chimeric CD8TMD* protein to the lysosome, probably through the 
lysosomal/vacuole-targeted GQC pathway (see below) (Briant et al., 2017; Yamasaki et al., 
2014). Because proteasome-targeted GQC occurs independently of substrate ubiquitination or 
the multivesicular body (MVB) pathway, this QC event is simply a gatekeeping checkpoint in 
which the cis-Golgi is equipped with multiple retrieval receptors that identify escaped ERAD 
substrates that may also be bound to ER chaperones. The existence of proteasome-targeted GQC, 
nevertheless, raises more questions than answers. Future research will be needed to address why 
ER-Golgi trafficking is required for efficient ER degradation of some substrates, what structural 
features dictate ER exit versus ER retention of select substrates, and does the entire population of 
escaped substrates undergo ER-Golgi trafficking or is only a subset of these substrates retained 
in the ER and directly targeted for ERAD? 
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1.3.2   Lysosome/vacuole-targeted GQC 
Most commonly, the term GQC refers to an event that targets misfolded protein for 
lysosomal degradation. In contrast to the QC checkpoint in ERGIC and cis-Golgi that retrieves 
back misfolded proteins for ERAD (Section 1.3.1), I have used the term lysosome/vacuole-
targeted GQC to describe this more common, canonical form of GQC, which sorts misfolded 
proteins for lysosomal/vacuolar degradation or maturation in higher cells and in yeast, 
respectively.  Data on this pathway have primarily arisen from studies in yeast and have revealed 
two routes to target misfolded proteins from the Golgi to the lysosome: receptor-mediated 
sorting and ubiquitin ligase mediated sorting. 
 
Receptor-mediated GQC   
Vps10 is a type I membrane receptor localized in the Golgi and sorts the vacuolar 
hydrolases proteinase A (PrA) and carboxypeptidase Y (CPY) (Bowers and Stevens, 2005). Loss 
of Vps10 results in secretion of more than 90% of newly synthesized CPY and 50% of PrA 
(Cooper and Stevens, 1996; Marcusson et al., 1994). Upon binding to its sorting receptor at the 
Golgi, CPY is transported from the late Golgi to endosomes in a clathrin and dynamin-related 
GTPase Vps1-dependent manner (Deloche et al., 2001). In addition to folded cargo proteins, 
Vps10 also recognizes and sorts misfolded proteins for lysosomal degradation, including 
misfolded lambda repressor-invertase chimeras and β-lactomase (Holkeri and Makarow, 1998; 
Hong et al., 1996; Wang and Ng, 2010). Analysis of the mutant lambda repressor-invertase 
chimera was the first observation that supported GQC of a lumenal/soluble protein. The chimeras 
were constructed by fusing invertase to either wild-type or mutant lambda repressor. In contrast 
to the wild-type version that was mostly secreted, the mutant was delivered to the vacuole in a 
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Vps10-dependent fashion (Hong et al., 1996). Similarly, β-lactamase, when expressed in S. 
cerevisiae, was transported in a Vps10-dependent manner from the Golgi to the vacuole for 
degradation (Holkeri and Makarow, 1998). Deletion of VPS10 not only blocked vacuolar sorting 
of the chimera as well as β-lactamase but also led to secretion. Moreover, overexpression of the 
misfolded substrate increased the percentage of its secretion, indicating a saturable process 
(Hong et al., 1996). However, the mechanism of how Vps10 recognizes both folded and 
misfolded proteins remains unknown. One possibility is that folded and misfolded substrates 
engage two different sites on Vps10 (Jorgensen et al., 1999).  
A similar sorting mechanism was subsequently discovered in mammalian cells. Sortilin is 
a mammalian type I membrane receptor homologous to Vps10. Sortilin resides in both the Golgi 
and plasma membrane and mediates lysosomal cargo sorting, including sphingolipid activator 
proteins, ApoB, lipoprotein lipase, and neurotensin (Amengual et al., 2018; Lefrancois et al., 
2003; Nielsen et al., 1999; Nielsen et al., 2001). Similar to its yeast counterpart, sortilin also 
mediates lysosomal sorting of misfolded proteins, such as aggregated GPP130. After manganese 
treatment, GPP130 undergoes oligomerization/aggregation followed by lysosomal degradation, 
which requires both clathrin and sortilin (Tewari et al., 2015; Venkat and Linstedt, 2017). 
Interestingly, while Golgi protein oligomerization/aggregation induced by a tandem FKBP 
domain was sufficient to trigger lysosomal degradation, trafficking was sortilin-independent, 
suggesting that protein aggregation is necessary but not sufficient for sortilin-mediated 
lysosomal sorting (Venkat and Linstedt, 2017) The finding that sortilin recognizes protein 
aggregates in the Golgi lumen and facilitates lysosomal degradation is reminiscent of a previous 
study in which a type I membrane protein, furin, became progressively aggregated in Golgi 
leading to its lysosomal delivery (Wolins et al., 1997). Because these substrates are mostly 
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lumenal protein and may not be accessible to the cytosolic ubiquitination machinery, and 
because delivery to the lysosome is MVB-independent, the structural features and machinery that 
define this non-canonical, Vps10/sortillin-specific form of QC remain unclear.  
 
Ubiquitin ligase mediated GQC  
In contrast to Vps10/sortillin-receptor sorting, ubiquitin ligase-mediated GQC is better 
defined. Studies in yeast identified two ubiquitin ligase in the Golgi that directly and indirectly 
recognize misfolded proteins for degradation in the lysosome: Tul1 and Rsp5. To date, all the 
identified substrates of Tul1 and Rsp5 are membrane proteins. In this case, the MVB pathway is 
required after substrate ubiquitination and for lysosomal delivery. 
Tul1 is a RING domain ubiquitin ligase with multiple transmembrane segments. It was 
first identified as an ubiquitin ligase that recognizes and marks misfolded proteins with mutant 
transmembrane domains for vacuole-dependent degradation. Known substrates include 
Pep12(D), CPS1, and Phm5 (Reggiori and Pelham, 2002). These substrates are all single pass 
membrane proteins with polar residues in the membrane-spanning portion of the protein, which 
is recognized by Tul1. Tul1 functions with the E2 ubiquitin conjugating enzyme, Ubc4, to add 
poly-ubiquitin chains onto the cytosolic portion of the substrate, thereby acting as a sorting 
signal for the MVB pathway. Unlike CPY, which is a folded, soluble protein that engages Vps10 
for lysosomal sorting, the membrane proteins CPS1 and Phm5 use another strategy: Both CPS1 
and Phm5 possess polar residues and mimic misfolded Tul1 substrates, so they are ubiquitinated 
and delivered to the vacuole via MVB capture. Moreover, the scope of Tul1 substrates can be 
further expanded under stress conditions, such as amino acid starvation or TOR inactivation. 
Under these conditions, specific Golgi proteins including Yif1, Tlg2, Btn1, Kex2 and 
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unpalmoylated Tgl1 become Tul1 substrates and are directed to the vacuole, which helps 
counteract nitrogen depletion (Dobzinski et al., 2015).  
Tul1 was later characterized as a component of the Dsc complex, which consists of Tul1, 
Dsc2, Dsc3, Dsc4, and Ubx3 in fission yeast (Stewart et al., 2011). The overall structure of the 
Dsc complex mirrors that of the Hrd1 complex. Strikingly, Tul1, Dsc2, and Dsc3 are 
homologous to Hrd1, Der1 and Usa1, respectively (Stewart et al., 2012; Stewart et al., 2011). 
Each of these components, except for Dsc4, also exists in budding yeast, but the involvement of 
Cdc48 in the fission yeast Dsc complex suggests that a unique form of GQC is at-play. Under 
conditions where ergosterol and/or oxygen is limited, the Dsc complex in fission yeast binds and 
cleaves the membrane-bound sterol regulatory element binding protein (SREBP) in the Golgi, 
liberating its cytosolic transcriptional factor domain to activate genes required for lipid synthesis 
and uptake. To this end, the ubiquitin-proteasome system is employed (Stewart et al., 2011).  
More Tul1 substrates in budding yeast have been identified that localize in other 
compartments besides the Golgi, indicating extended function of the Dsc complex in other 
organelles.  New Tul1-dependent substrates include the vacuolar zinc transporters, such as Cot1 
(which mediates influx) and Zrt3 (which mediates efflux). Both transporters are regulated in 
response to intracellular zinc. Specifically, high levels of zinc induce Zrt3 degradation, whereas 
low levels of zinc trigger the degradation of Cot1. The degradation of both transporters depends 
on vacuolar membrane recycling and requires Tul1 (Li et al., 2015). In contrast, two novel Dsc 
complex subunits were identified that target the complex to different organelles: Gld1 directs the 
Dsc complex to the Golgi and endosome, whereas Vld1 targets the Dsc complex to the vacuolar 
membrane (Yang et al., 2018). Therefore, as the critical component of Dsc complex, Tul1 is a 
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versatile E3 ligase that can complex with different subunits to protect protein fidelity in the late 
secretory pathway: i.e., the Golgi, endosome, and vacuole.  
Rsp5 is another versatile E3 ubiquitin ligase involved in lysosome/vacuole-targeted GQC 
and harbors three domains: the N-terminal C2 domain, the central WW domain, and the C-
terminal catalytic HECT domain, which possesses ubiquitin ligase activity (Belgareh-Touze et 
al., 2008; MacGurn et al., 2012). The WW domain of Rsp5 is the protein-protein interaction 
module that binds a short recognition motif, PPXY. Rsp5 can recognize the PPXY motif residing 
in either substrates or adaptors, which facilitate its broad substrate range and accessibility. 
Indeed, the existence of multiple Rsp5 adaptors that localize in different organelles can target 
Rsp5 to the plasma membrane, to endosomes, to the vacuole, or to the Golgi, indicative of its 
broad role in several QC processes (Belgareh-Touze et al., 2008; Sardana et al., 2019). For 
example, during vacuolar targeted GQC, Rsp5 is recruited by the Bul1 and Bul2 adaptors to 
ubiquitinate misfolded membrane proteins, such as a mutated form of the plasma membrane 
proton ATPase, Pma1, for subsequent vacuole delivery (Chang and Fink, 1995; Luo and Chang, 
1997; Pizzirusso and Chang, 2004). An obligate GQC substrate, Wsc1*, is another Rsp5 
substrate that is routed from the Golgi to the vacuole through the MVB pathway (Wang and Ng, 
2010; Wang et al., 2011c). The absence of a PPXY motif on Wsc1* suggests the existence of an 
as-yet unidentified adaptor. Another example demonstrating the utility of Rsp5 regards the fate 
of some ERAD substrates, which under some conditions may even exit the ER and advance to 
the Golgi for subsequent vacuolar degradation. The classic ERAD-L substrate, CPY*, when 
overexpressed, is routed for vacuolar degradation after Golgi transit (Haynes et al., 2002; Spear 
and Ng, 2003). Surprisingly, CPY* delivery doesn’t utilize Vps10, which is evident for wild type 
CPY. Instead, the degradation of overexpressed CPY* employs Rsp5 for ubiquitin-dependent 
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sorting into the vacuole (Haynes et al., 2002). Furthermore, Rsp5 can regulate the fate of newly 
synthesized transporters in response to environmental conditions. The yeast amino acid 
transporter Gap1 is directed from the Golgi to the vacuole in an Rsp5-dependent manner in the 
presence of high ammonia (De Craene et al., 2001). Another example comes from the yeast 
siderophore transporter Sit1, which is transported to the vacuole in a similar manner in the 
absence of its substrate, ferrioxamine B (Froissard et al., 2007). Overall, Rsp5 can dispose of 
both misfolded membrane proteins in the Golgi and unnecessary transporters, which is 
reminiscent of protein quantity control in the ER (see Section 1.1.5).  
After ubiquitination by Tul1, Rsp5 or another uncharacterized ubiquitin ligase, misfolded 
membrane proteins undergo an inward budding process to form intraluminal vesicles. During 
this process, ESCRT is recruited to induce the invagination of endosomal limiting membrane. 
Briefly, ESCRT-0 is first recruited to the endosomes by binding ubiquitin on substrates and then 
directs the assembly of the downstream complexes. ESCRT-I clusters ubiquitinated proteins and 
acts as a bridge between ESCRT-0 and ESCRT-II.  ESCRT-II with its GLUE domain has high 
affinity for endosome-enriched phospholipid phosphatidylinositol-3-phsophate (PI3P) and is 
assembled on the late endosomal membrane. ESCRT-III is then recruited and oligomerized to 
induce the inward budding and intraluminal vesicles invagination. Finally, an ATPase, Vps4, 
strips other ESCRT components from the membrane and directs membrane scission (Christ et 
al., 2017; Henne et al., 2011). The late endosomes with intraluminal vesicles are termed 
multivesicular bodies (MVB), which are then fused with lysosome/vacuole for delivery of its 
cargos for degradation (Piper and Katzmann, 2007).  
Our early understanding of Rsp5 function arose primarily from its role during the 
endocytosis and vacuole-dependent degradation of damaged or dispensable plasma membrane 
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transporters (Belgareh-Touze et al., 2008; MacGurn et al., 2012). However, Rsp5 was recently 
found to clear mislocalized vacuolar membrane proteins (Sardana et al., 2019). In contrast, the 
mammalian ortholog of Rsp5, NEDD4, is involved in neither GQC nor plasma membrane QC, 
but instead down-regulates functional plasma membrane proteins, such as the epithelial sodium 
channel and voltage-gated calcium and sodium channels, via ubiquitin-dependent endocytosis 
(Fotia et al., 2004; Rougier et al., 2011; Staub et al., 1996).  
Together, Golgi is armed with two QC checkpoints to dispose of misfolded proteins that 
advance to the Golgi: proteasome-targeted GQC in the cis-Golgi and lysosome/vacuole-targeted 
GQC which most likely takes place in the trans-Golgi. Based on the severity of the lesion, 
misfolded proteins are either retrieved for ERAD via receptors or are directed for lysosomal 
degradation via the Vps10 receptor (e.g., misfolded lumenal/soluble proteins) and/or a ubiquitin 
ligase complex (e.g., misfolded membrane proteins). Furthermore, while both proteasome-
targeted GQC and receptor-mediated GQC appear to be conserved between yeast and mammals, 
the existence of a mammalian GQC ubiquitin complex remains unidentified. 
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Figure 2 Golgi quality control pathway 
Misfolded proteins targeted for GQC are first transported to the cis-Golgi via COPII vesicle transport. 
Proteasome-targeted GQC: ER chaperones and retrieval receptors in the cic-Golgi bind and retrieve some 
misfolded proteins back to the ER through COPI vesicle transport.  These substrates are then eliminated 
by the proteasome via ERAD-L. Lysosome/vacuole-targeted GQC: Misfolded proteins that travel further 
to the trans-Golgi are sorted to the MVB via Vps10 receptor or a ubiquitin ligase and ESCRT. Following 
MVB sorting, misfolded proteins are delivered to the vacuolar lumen for degradation. 
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1.4  COOPERATION AMONG ERAD, ER-PHAGY, AND GQC 
The ER serves as a hub for both protein synthesis and quality control. As discussed in 
section 1.1, the primary QC machinery, ERAD, is an elaborate and efficient mechanism that can 
monitor the protein-folding state and clear misfolded proteins with folding lesions located at 
different positions relative to ER membrane. The ubiquitin proteasome system is employed by 
ERAD to ensure that only terminally misfolded proteins that are marked with poly-ubiquitin are 
eliminated. However, the capacity and ability of ERAD is restricted by the specific functions of 
ERAD components, which may not be able to recognize or handle all aberrant proteins. This 
necessitates additional QC machineries that cooperate with ERAD to maintain ER protein 
homeostasis: ER-phagy and GQC. The two additional QC machineries expand both the ability 
and capacity of ER to recognize and clear misfolded proteins.  
GQC may deal with substrates that exhibit more minor folding lesions. Substrates for 
either proteasome-targeted GQC or lysosome/vacuole-targeted GQC undergo anterograde 
trafficking from the ER to Golgi, which often requires a functional ER exit signal (Kawaguchi et 
al., 2010; Kincaid and Cooper, 2007). The prolonged engagement of ER chaperones, such as BiP 
and/or calnexin, may distinguish proteasome-targeted GQC substrates from lysosome/vacuole-
targeted GQC substrates. Proteasome-targeted GQC substrates possess both a functional ER exit 
signal and a misfolding lesion that signals ERAD. In contrast, lysosome/vacuole-targeted GQC 
substrates may display more subtle misfolded lesions but still contain a functional ER exit signal, 
which reside in substrates such as Pep12(D), CPS1, Phm5, and Wsc1*. For substrates that 
display both an ERAD signal and a functional ER exit signal, the ERAD and ER exit 
machineries can compete for these misfolded proteins (Kincaid and Cooper, 2007). However, 
ERAD can also recognize more subtle defects or different lesions in protein as it can degrade 
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substrates that might fold and function later in the secretory pathway if folding is artificially 
induced (Lukacs and Verkman, 2012; Ward et al., 1995; Welsh and Smith, 1993). Therefore, 
under normal conditions, ERAD outcompetes the ER exit machinery. In contrast, when ERAD is 
compromised, misfolded substrates with functional ER exit signals can undergo forward 
trafficking at a higher level (Kincaid and Cooper, 2007; Spear and Ng, 2003; Wang et al., 
2011a).  Even for ERAD substrates, such as CPY*, whose ER exit signal may only be partially 
functional, compromising some ERAD component still increases ER exit (Kincaid and Cooper, 
2007). Furthermore, under specific conditions when CPY* is overexpressed, which saturates the 
ERAD pathway, CPY* can advance to the Golgi and becomes a lysosome/vacuole-targeted GQC 
substrate (Spear and Ng, 2003). So far, most lysosome/vacuole-targeted GQC substrates contain 
folding lesions in either the lumenal domain or a transmembrane domain, which is consistent 
with the finding that ERAD substrates with lumenal folding lesions are able to advance to the 
Golgi before ER degradation, while those with cytosolic folding lesions are statically retained in 
the ER (Vashist and Ng, 2004). It is also possible that cytosolic folding lesions may directly 
disturb the ER exit signal and that the cytosolic chaperones may be more strict in binding their 
substrates, thus directly competing with COPII-mediated ER exit. Recently, I reported on a novel 
substrate, SZ*, with a cytosolic folding lesion that can be targeted for both ERAD and vacuole-
targeted GQC. I discovered that substrate aggregation also changes the balance between ERAD 
and vacuole-dependent degradation (Sun and Brodsky, 2018).  
In contrast to GQC, ER-phagy may deal with more severely misfolded substrates that 
display folding lesions in the ER but cannot be disposed of by ERAD due to their aggregation 
state or the absence of a recognizable ERAD signal, which is most cases remains mysterious. 
Protein misfolding and aggregation may also bury ER exit signals, preventing anterograde 
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transport. It was recently shown that an ERAD-L component, calnexin, might play a critical role 
in terminating ERAD and directing substrates for ER-phagy by recruiting ER-phagy receptor 
FAM134B (Forrester et al., 2019). This discovery potentially bridges the gap between two 
distinct QC machineries, ERAD and ER-phagy, and suggests a discrimination point in ERAD. 
However, the identification of a detergent soluble ER-phagy substrate, GnRHR, suggests instead 
that even soluble misfolded substrates may be targeted for ER-phagy (Houck et al., 2014). The 
signal for GnRHR ER-phagy is unknown. 
Under stress conditions, when misfolded proteins accumulate in the ER, ERAD alone is 
insufficient to maintain ER homeostasis. Under these conditions, the UPR is induced to both 
attenuate protein translation and enhance protein folding and degradation (Karagoz et al., 2019). 
Enhanced degradation resulted from transcriptional activation of genes involved in ERAD, ER-
phagy and GQC, suggesting collaboration between these three QC machineries to protect ER 
proteome fidelity (Smith and Wilkinson, 2017; Smith et al., 2018; Travers et al., 2000). ERAD, 
ER-phagy and GQC are further connected during ER stress to more generally maintain ER 
homeostasis. It has long been recognized that ERAD is enhanced upon UPR induction to clear 
misfolded proteins in the ER. Several ERAD-L components are up-regulated by the UPR, 
including Hrd1, Der1, Hrd3 and Ubc7 (Travers et al., 2000). Erv29 is also up-regulated during 
UPR and is required to transport both folded and misfolded cargo. Although another ERAD-
targeting GQC receptor, Rer1 (see above), is not directly up-regulated during UPR, but loss of 
Rer1 induces ER stress in both yeast and worms, suggesting the involvement of proteasome-
targeted GQC in maintaining ER homeostasis (Ghavidel et al., 2015). The enhanced anterograde 
and retrograde trafficking between ER and Golgi during UPR may further facilitate both 
proteasome-targeted GQC and lysosome/vacuole-targeted GQC indirectly. In line with this result, 
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the identification of Tul1 as a GQC ubiquitin ligase further confirmed the involvement of GQC 
during the UPR as Tul1 is specifically induced by UPR but not by the heat-shock response 
(Reggiori and Pelham, 2002; Roth et al., 1998; Travers et al., 2000). Besides ERAD and GQC, 
autophagy flux is further enhanced during the UPR (Senft and Ronai, 2015). Under ER stress 
conditions, multiple autophagy-related genes (ATG) are transcriptionally up-regulated, and one 
of the UPR branches in metazoan, the PERK-eIF2α pathway, is essential for autophagy induction 
(B'Chir et al., 2013). Strikingly, one ER-phagy receptor, CCPG1, is also up-regulated in response 
to ER stress, suggesting an important role of ER-phagy to counteract ER stress (Smith et al., 
2018). Furthermore, micro-ER-phagy in yeast and its mammalian counterpart, Sec62-mediated 
recovER-phagy, are both required to re-establish pre-stress ER condition by eliminating 
excessive ER membranes and folding factors that are generated during the UPR (Bernales et al., 
2006; Fumagalli et al., 2016; Schuck et al., 2014). Recently, a conserved Atg8-binding adaptor, 
Ubx5 in yeast (PUX proteins in plant) was identified that targets mutated, non-functional 
Cdc48/p97 for autophagic degradation, which if stabilized could compromise ERAD (Marshall 
et al., 2019). Additionally, another ERAD component, the proteasome, when inactivated also 
becomes an autophagy substrate, suggesting the involvement of autophagy in monitoring ER 
quality control by turning over inactive ERAD components (Marshall et al., 2015). Despite the 
distinct machineries employed by ERAD, ER-phagy and GQC, their synchronized up-regulation 
during ER stress indicates their cooperative potential to counteract ER stress and maintain ER 
protein homeostasis (Figure 3).  
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Figure 3 Degradation fate of misfolded proteins in the ER 
Misfolded proteins in the ER can be targeted for multiple quality control pathways. Most of the misfolded 
proteins in the ER are eliminated by ERAD via the ubiquitin-proteasome system. Some misfolded 
proteins exit the ER and are sorted en route to the lysosome/vacuole for degradation. Upon severe 
aggregation, some misfolded proteins are targeted for lysosomal/vacuolar degradation via ER-phagy. All 
three quality control machineries act in coordination to safeguard the ER proteosatsis, especially upon ER 
stress, during which all three pathways are upregulated (blue star) to enhance the protein turnover in the 
ER through different routes. 
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1.5  THESIS SUMMARY 
In this thesis, I investigated features of misfolded secretory pathway proteins that dictate 
their degradation fate in yeast: ERAD versus post-ER degradation. Despite the incomplete 
conservation between yeast and mammals, the reduced level of gene redundancy and 
conservation of major protein quality control components make yeast a good model organism for 
my research.  To this end, I first designed a novel substrate, SZ*, and demonstrated that SZ* is 
degraded by both the proteasome through the ERAD pathway and by vacuolar proteases through 
the post-ER degradation pathway (Chapter 2). This phenomenon is similar to that seen with 
ApoB, ROMK, and Kir2.1 (Amengual et al., 2018; Hrizo et al., 2007; Kolb et al., 2014; Mackie 
et al., 2018). Through an interrogation of cells with different stress, I was able to demonstrate 
that heat-shock and substrate overexpression can increase ERAD targeting of SZ*, which 
correlated with substrate aggregation. Next, I investigated whether inhibiting distinct steps 
during ERAD affected the anterograde transport of SZ* from the ER (Chapter 3). I demonstrated 
that inhibiting pre-ubiquitination steps during the ERAD of SZ* allows ER exit. In order to 
confirm that ubiquitination acts as an ER retention signal, I attached four tandem ubiquitin 
molecules to SZ* and showed that poly-ubiquitin is sufficient to retain SZ* in the ER even when 
ERAD is compromised. Based on these efforts, I discovered that substrate aggregation and 
ubiquitination dictate the fate of misfolded membrane proteins for ERAD versus post-ER 
degradation.  
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2.0  A NOVEL MODEL SUBSTRATE WHOSE DEGRADATION IS DETERMINED BY 
AGGREGATION PROPENSITY 
The contents of this chapter are adapted from a recently published article in Molecular 
Biology of the Cell (Sun and Brodsky, 2018). The figures and text have been edited for clarity 
and flow.  
2.1  INTRODUCTION 
In eukaryotes, one third of the proteome enters the ER, thus making the ER a rather 
crowded environment. Because of genetic mutations, translational errors, and cellular stress, 
protein misfolding occurs quite frequently (Berner et al., 2018; Needham et al., 2019). 
Accumulation of misfolded and/or aggregation-prone proteins not only endangers cellular health 
but also causes human diseases such as Huntington’s disease, Alzheimer’s disease, and 
Parkinson’s diseases (Hartl, 2017). To protect proteome fidelity and maintain cellular 
homeostasis, eukaryotes have evolved multiple QC mechanisms that operate along the secretory 
pathway including ERAD, ER-phagy, GQC and plasma membrane QC (Arvan et al., 2002; 
Dikic, 2018; MacGurn et al., 2012; Vembar and Brodsky, 2008). Therefore, proteins—especially 
membrane proteins with complex topologies and subunits of multimeric assemblies—are subject 
to sequential QC checkpoints before reaching to their final destinations (Houck and Cyr, 2012; 
Okiyoneda et al., 2011). 
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Most secreted and membrane proteins that fail to pass the ERQC checkpoint are 
eliminated by ERAD, during which misfolded proteins are proteolyzed in a step-wise 
mechanism. Briefly, ERAD substrates are first recognized by molecular chaperones, residing in 
both the ER lumen and cytoplasm, as well as by chaperone-like lectins (Braakman and Bulleid, 
2011; Nakatsukasa et al., 2008). Depending on the location of the folding lesion, ERAD 
substrates are then ubiquitinated by distinct E3 ubiquitin ligases that associate with a non-
overlapping group of protein partners in the ER (Carvalho et al., 2006; Vashist and Ng, 2004). 
Despite the existence of three ERAD branches, ERAD-C, ERAD-L and ERAD-M, they all 
converge on the substrate retrotranslocation step. During substrates retrotranslocation, the 
ubiquitinated substrates are extracted from the ER to the cytoplasm in an ATP- and Cdc48/p97-
dependent manner (Ye et al., 2003). Finally, the retrotranslocated substrates with poly-ubiquitin 
tags are delivered to the 26S proteasome for degradation (Meusser et al., 2005). 
When the ERAD pathway is compromised or overwhelmed by the accumulation of 
misfolded proteins in the ER, the UPR is induced to counteract ER stress by attenuating protein 
translation, increasing protein folding capacity and enhancing protein degradation (Preissler and 
Ron, 2018). Enhanced protein degradation results from up-regulation of UPR targets that are 
involved in ERAD, ER-phagy, and GQC (Bernales et al., 2006; Preissler and Ron, 2018; 
Reggiori and Pelham, 2002; Schuck et al., 2014; Travers et al., 2000). Additionally, the 
cytoplasmic heat-shock response can also alleviate ER stress by altering multiple ER-associated 
activities, such as protein translocation, folding, and anterograde transport along the secretory 
pathway (Liu and Chang, 2008). Even with a robust ERAD machinery and the UPR that 
responds to stressful condition, misfolded proteins can escape ERAD and advance to the Golgi, 
suggesting the existence of post-ERQC mechanisms. 
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Like ERQC, post-ERQC, including GQC and plasma membrane QC, employs key 
components to targets misfolded proteins for clearance by the proteasome (proteasome-targeted 
GQC) and the lysosome (lysosome/vacuole-targeted GQC and plasma membrane QC). GQC is 
equipped with two QC checkpoints, which reside in the cis-Golgi (proteasome-targeted GQC) 
and trans-Golgi (lysosome/vacuole-targeted GQC) to protect later steps in the secretory pathway 
by inspecting the folding state of a protein and triaging misfolded proteins to different proteolytic 
machineries for turnover. Briefly, proteasome-targeted GQC substrates are transiently trafficked 
to the cis-Golgi and then retrieved for proteasomal degradation (Caldwell et al., 2001; Taxis et 
al., 2002; Vashist et al., 2001). In contrast, misfolded proteins that travel further to the trans-
Golgi are monitored by lysosome/vacuole-targeted GQC and modified by E3 ubiquitin ligases, 
such as Tul1 and Rsp5, and can be selected by the Vps10 receptor for vacuolar/lysosomal 
degradation. Canonical substrates directed for vacuolar/lysosomal degradation by GQC include 
membrane proteins harboring polar residues in their transmembrane domains, such as Pep12(D), 
Phm5 and Cps1, as well as membrane proteins with lumenal folding lesions, like Wsc1* 
(Reggiori and Pelham, 2002; Wang and Ng, 2010; Wang et al., 2011c). QC at the plasma 
membrane ensures the fidelity of the proteome at the cell surface through the ART-Rsp5 
ubiquitin ligase network (Zhao et al., 2013). When cells are subject to stresses (such as heat-
shock stress), changes in nutrient levels, or altered environmental conditions, cell surface 
proteins undergo dynamic regulation, during which the ART-Rsp5 network recognizes and 
ubiquitinates select proteins and targets them for lysosomal degradation in response to these 
stimuli (MacGurn et al., 2012). For membrane proteins, both the GQC and plasma membrane 
QC pathways converge at the MVB pathway, where ubiquitinated proteins are invaginated into 
the endosomal lumen with the help of endosomal sorting complexes required for transport 
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(ESCRT), thus forming multivesicular bodies for vacuolar/lysosomal delivery (Christ et al., 
2017; Henne et al., 2013). 
In the early secretory pathway, ERAD and GQC work in tandem to prevent misfolded 
proteins from moving to later steps in the secretory pathway. Misfolded membrane proteins that 
escape ERAD and become GQC substrates bear folding lesions in either transmembrane or 
lumenal domains but not cytosolic domain. In addition, it has been recognized that misfolded 
membrane proteins with cytosolic folding lesions (ERAD-C substrates) are retained in the ER 
but the underlying reason for this event remains elusive (Vashist et al., 2001). Considering the 
fact that multiple human disease-causing mutant proteins bear cytosolic folding lesions that are 
trapped in the ER for ERAD, it is vital to establish if misfolded membrane proteins with 
cytosolic folding lesions can exit the ER and what features dictate ER retention versus ER exit 
(Guerriero and Brodsky, 2012; Houck and Cyr, 2012). 
In this chapter, I sought to define how a membrane protein with a cytoplasmic misfolded 
domain might be selected for ERAD versus post-ERQC. To this end, I first designed a novel 
misfolded membrane protein, SZ*, which is a simplified version of a well-characterized ERAD 
substrate, Ste6-166 (Loayza et al., 1998). The substrate was constructed by appending a single 
pass membrane span from a plasma membrane protein, Wsc1, to a cytosolic misfolded domain 
NBD2*, which on its own is a substrate for ubiquitin-proteasome-mediated degradation 
(Guerriero et al., 2013). I first characterized the degradation requirements of SZ* and then found 
that SZ* was selected for efficient degradation by both ERAD and vacuole/lysosome-targeted 
GQC, the latter of which requires the MVB pathway. By interrogating how various conditions 
affect the degradation fate of SZ*, I discovered that heat-shock and substrate overexpression 
enhance ERAD targeting of SZ*, which correlated with increased substrate aggregation. 
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Together, these data provide a new tool to investigate the mechanism underlying degradation 
pathway selection and add new insights into the rules that govern ERAD substrate selection.  
2.2  MATERIALS AND METHODS 
2.2.1   Yeast growth conditions, strains, and plasmid construction 
Yeast cells were grown at 26°C unless otherwise indicated. Temperature-sensitive strains 
were grown at room temperature for propagation and then shifted to 37°C. The Saccharomyces 
cerevisiae strains employed in this chapter are provided in Table 1 (Appendix A). Liquid and 
solid selective media were prepared as previously described (Michaelis and Herskowitz, 1988). 
Yeast transformation was conducted using lithium acetate method (Ito et al., 1983). 
Both triple HA-tagged SZ and SZ* are generated by overlapping PCR. Briefly, SZ* was 
amplified through overlap PCR from plasmid pRP12 using primers OSZ01, OSZ02, OSZ03, and 
OSZ04 (all plasmids and primers used in this chapter were listed in Table 2, and Table 3 
(Appendix A), respectively) (Prasad et al., 2012). The SZ* fragment was cloned into the 
p416TEF plasmid at the SpeI/XhoI sites, thus generating plasmid pSZ01. Similarly, SZ was PCR 
amplified from plasmid pSZ01 and pCG01 by overlapping PCR again using primers OSZ01, 
OSZ06, OSZ05, and OSZ07, thus generating plasmid pSZ02. To construct GFP tagged SZ*, SZ* 
with a 15 amino acid ((GGGGS)3) flexible linker right after the NBD2* first constructed with 
primers OSZ08 and OSZ09 and inserted into the p416TEF plasmid at XhoI/BamHI site. 
Superfolder GFP was then inserted next to the SZ*-linker at the BamHI/EcoRI sites, generating 
SZ*-GFP (pSZ03) (Lee et al., 2013). W-N was amplified by overlap PCR using primers OSZ07, 
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OSZ10, OSZ11, and OSZ12 and plasmid pSW148 and pSZ02 as templates. Similarly, W-N* 
was amplified by overlap PCR using primers OSZ04, OSZ10, OSZ11, and OSZ12 and plasmid 
pSW148 and pSZ01. Then, the fragments encoding W-N and W-N* were inserted into the 
p416TEF plasmid at the SpeI and XhoI sites, generating pSZ04, and pSZ05, respectively. 3HA-
NBD2* was PCR amplified with primers OSZ13 and OSZ04 using pCG03 as a template. The 
3HA-NBD2* fragment was then inserted into the p416TEF (low expression) and p426TEF (high 
expression) plasmids, generating pSZ06 and pSZ07, respectively. A high expression vector for 
SZ* (pSZ08) was created by subcloning into p426TEF at the SpeI/XhoI sites. The DNA 
sequences of all constructs were confirmed by Genewiz. 
2.2.2  Carbonate extraction 
To liberate soluble protein that are loosely associated with membrane, carbonate 
extraction assay was performed. A total of 30 ODs of wild-type yeast cells expressing the 
indicated substrates were lysed with glass beads in 400μl of Buffer 88 (20mM HEPES, pH 6.8, 
150mM KOAc, 5mM MgOAc, 250mM sorbitol) with 1mM DTT and protease inhibitors 
(1.5μg/ml pepstatin A, 3mM PMSF, and 3μg/ml leupeptin). Unbroken cells and cell debris were 
pelleted at 800g at 4°C for 5 min. Next, 300μl of the crude lysate (supernatant) was mixed with 
same volume of 200mM Na2CO3 (pH 11.5) and the mixture was incubated on ice for 30 min. 
The samples were then centrifuged at 100,000g for 30 min at 4°C. A trichloroacetic acid (TCA) 
precipitation was used to isolate proteins in the supernatant, and 80μl of TCA sample buffer 
(80mM Tris, pH 8, 8mM EDTA, 15% glycerol, 0.08% Tris base, 0.01% bromphenol blue 3.5% 
SDS, supplemented with freshly added β-mercaptoethanol to a final concentration of 4%) was 
added to solubilize the proteins from supernantant and pellet fractions (Zhang et al., 2001). Both 
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the supernatant (S) and pellet (P) were then resolved by 10% SDS-PAGE, followed by Western 
blot analysis. 
2.2.3  Proteinase accessibility assay 
ER microsomes containing SZ or SZ* were prepared as previously described 
(Nakatsukasa et al., 2008). In brief, 100 ODs of the indicated cells expressing SZ or SZ* from 
the p416TEF plasmid were harvested and lysed with glass beads in Buffer 88 with protease 
inhibitors (3mM PMSF, 1.5μg/ml pepstatin A, and 3μg/ml leupeptin). Unbroken cells and cell 
debris were pelleted at 800g for 5 min at 4°C, and the supernatant was removed and centrifuged 
at 18,000g for 30 min at 4°C to isolate a crude microsome fraction. After two washes with Buffer 
88, the microsomes were again collected and resuspended, and equal amounts were treated in the 
presence or absence of proteinase K (Sigma-Aldrich, final concentration 5μg/ml), or proteinase 
K in the presence of 1% Triton-100. After 15 min on ice, PMSF (final concentration 10mM) was 
added to terminate the reaction. Total protein was TCA precipitated, as above, and SDS-PAGE 
and Western blot analysis were performed. 
2.2.4  Detection of steady-state protein levels 
Cells expressing the indicated substrates were grown to log phase (A600 ~1.0), and equal 
numbers of cells were harvested. Total protein was precipitated with TCA.  When temperature 
sensitive strains were examined, cells were shifted to 37°C for 30 min to induced the mutant 
phenotype before cells were harvested. The total TCA precipitated material was then subject to 
SDS-PAGE and Western blot analysis as described above. 
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2.2.5  Stress treatments and measurements of ERAD-dependent degradation 
pdr5Δ cells expressing SZ* were grown to early log phase (A600 ~0.8) and the following 
stressors were added to the culture media before the cells were incubated at 30°C for 1 h: 
Tunicamycin (4μg/ml), H2O2 (1mM), CdCl2 (50μM), Canavanine (1mM) and calcofluor white 
(CFW; 100μg/ml). For heat-shock treatments, cells were grown at 37°C for 1 h in the absence of 
any other treatment. After a 1 h treatment, MG132 (100 μM) or DMSO was added to the culture 
and the cells were incubated with shaking at 26°C (or 37°C to induce heat-stress) in a waterbath 
for 40 min. Finally, 1ml of cells were taken from each culture, snap frozen in liquid nitrogen, and 
total protein was obtained by TCA precipitation. The indicated proteins were resolved by 10% 
SDS-PAGE, followed by Western blot analysis as described above  
2.2.6  Assays to measure protein degradation 
Cycloheximide chase assays were preformed to measure protein stability as described 
(Guerriero et al., 2013). In brief, the indicated yeast strains expressing the desired substrate were 
grown in SC (synthetic complete) medium lacking uracil (-ura) and containing glucose to mid-
log phase (A600 ~1.0), and cycloheximide was added to the culture to a final concentration of 150 
μg/ml. A 1ml aliquot was taken for the zero time point, and the culture was incubated at 26°C or 
37°C, as indicated, in a shaking water bath. At each time point, 1 ml aliquots were taken and the 
cells were snap-frozen in liquid nitrogen. For total protein extraction, TCA precipitation was 
used and protein pellets were solubilized with TCA sample buffer. Prior to SDS-PAGE, 
insoluble material was removed by centrifugation at 10,000 rpm in a microcentrifuge at room 
temperature. Samples were resolved via 10% SDS-PAGE, and subject to Western blot analysis, 
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as described above.  
Pulse chase assays were also performed to test the stabilities of distinct proteins, as 
described(Tansey, 2007). In brief, yeast expressing W-N and W-N* were grown in SC (synthetic 
complete) medium lacking uracil (-ura) and methionine (-met) but containing glucose to early 
log phase (A600 ~0.5), and S-35 (PerkinElmer) was added to each culture to a final concentration 
of 100 μCi/ml for 10 min. After labeling, the cells were washed with pre-warmed culture 
medium and then resuspended in culture medium supplemented with 13mM methionine, 40mM 
cysteine, and 0.2mg/ml cycloheximide. A 1ml aliquot of the culture was immediately taken as 
the zero time point, which was then mixed with 400μl of quench buffer (80mM Cys, 80mM Met, 
and 100mM NaN3) and placed on ice. The rest of the culture was incubated at 26°C in a shaking 
water bath, and at each subsequent time point 1 ml aliquots were taken and similarly mixed with 
quench buffer. Cells were lysed by glass bead beating and W-N and W-N* were 
immunoprecipitated from these samples with protein A sepharose (GE healthcare) and anti-HA 
antibody (Roche). After the pellets were washed and proteins were subject to SDS-PAGE, gels 
were dried and exposed to a phosphorimager screen. The protein substrates were detected by 
phosphorimager analysis on a Typhoon FLA 7000 (GE Healthcare). 
2.2.7  Detergent solubility assays 
The solubility of the indicated proteins was measured in dodecyl maltoside (DDM) as 
described previously (Zhao et al., 2013). In brief, ER microsomes from wild-type yeast 
expressing the indicated substrates were prepared as described above and incubated at indicated 
temperature for 30 min in Buffer 88 with protease inhibitors (see above) in the presence or 
absence of 1% DDM (EMD Millipore). The mixture was then centrifuged at 18,000g for 30 min 
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at 4°C, and the detergent soluble fraction (i.e., the supernatant) was precipitated with TCA (see 
above). Proteins from both the soluble and insoluble fractions were resuspended in TCA sample 
buffer and resolved by 10% SDS-PAGE, and Western blot analysis was performed as described 
above.  
2.2.8  Assays to detect the heat-shock response 
W303-A wild-type yeast were transformed with the HSE-LacZ reporter plasmid along 
with the Hsf1-R206S plasmid (Santoro et al., 1998; Sewell et al., 1995), where indicated, and 
were grown to log phase (A600 ~1.0). A total of 5 ODs of cells were harvested and lysed in 
Buffer 88 with protease inhibitors (3mM PMSF, 1.5μg/ml pepstatin A, and 3μg/ml leupeptin) by 
bead beating. Unbroken cells and cell debris were removed as described above. The supernatant 
was then collected and cleared by centrifugation at 18,000g for 10 min (4°C). The overall protein 
concentration of the cleared lysate was determined by BCA protein assay kit (ThermoFisher). A 
total of 100 μl of cleared lysate (25-80μg) was added to 0.9 ml of Z buffer (60mM Na2HPO4, 
40mM NaH2PO4, 10mM KCl, 1mM MgSO4, 50mM β-mercaptoethanol, pH 7.0). Next, the 
mixture was incubated at 30°C for 5 min and the reaction was initiated by adding 200μl ONPG 
(4mg/ml in Z buffer). The reaction was incubated at 30°C until the mixture acquired a pale 
yellow color and then terminated with 500μl 1M Na2CO3. The optical density was measured at 
A420nm and beta-galactosidase activity was calculated by using the following formula: 
OD420*1.7/(0.0045*total protein*time). 
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2.2.9  Indirect immunofluorescence microscopy 
Yeast expressing HA-tagged SZ* from the p416TEF plasmid were grown in SC-ura 
medium with glucose to an A600 of 0.5-0.8, fixed for 1 h in 4% formaldehyde at 30°C, and the 
cell walls were digested by incubation with Zymolyase 20T (MP Biomedicals) at 37°C for 30 
min.  The cells were applied to polylysine pretreated slides and were then permeabilized with 
methanol/acetone. The slides were blocked for 1 h at 37°C with blocking buffer (0.5% BSA, 
0.5% ovalbumin, 0.6% fish skin gelatin in PBS buffer) and incubated with the following primary 
antibodies at 4°C: anti-HA at a 1:250 and anti-Kar2 at a 1:500. After washing, the primary 
antibodies were conjugated with Alexa Fluor 488 goat anti-mouse and Alexa Fluor 568 goat anti-
rabbit (ThermoFisher), both at 1:500, and nuclei were stained with DAPI. The slides were 
mounted with Prolong Antifade Gold (Invitrogen) and imaged with an Olympus FV1000-100 
confocal microscope. 
2.2.10  Live-cell fluorescence microscopy 
The indicated yeast cells expressing GFP-tagged SZ* were grown to log phase 
(A600~0.8), and cells were incubated at 30°C in the presence of FM4-64 (ThermoFisher) for 30 
min.  Unbound FM4-64 was removed by washing the cells with SC media. The treated cells were 
then harvested by centrifugation and imaged by fluorescent microscopy on an Olympus FV1000-
100 confocal microscope.  
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2.2.11  Western blot analysis 
Trichloroacetic acid (TCA) precipitation was used to first pellet yeast total proteins, 
which were then resolved by SDS-PAGE. After SDS-PAGE, proteins were transferred onto 
nitrocellulose (BioTrace NT, Pall Corp.) using the overnight wet transfer system (Amersham 
Biosciences), and Western blot analysis was performed as described previously (Guerriero et al., 
2013) with the following primary antibodies: polyclonal rabbit anti-Sec61p (Stirling et al., 1992) 
at 1:5000, rabbit anti-glucose-6-phosphate dehydrogenase (G6PD) (A9521, Sigma-Aldrich) at 
1:5000, monoclonal mouse anti-GFP antibody (Roche) at 1:5,000, rat anti-HA-peroxidase 
(Roche) at 1:10,000, and  mouse anti-Pma1 which was a gift from Amy Chang (University of 
Michigan, Ann Arbor, MI) at 1:1,000. Secondary antibodies used in this study were: HRP-
conjugated goat anti-rabbit or anti-mouse secondary antibody at 1:5000 (Cell Signaling 
Technology). Proteins were visualized using SuperSignal Chemiluminescence (Thermo 
Scientific). Images of the blots were taken on a BIO-RAD ChemiDocTMXRS Image Station and 
quantified using ImageJ version1.48v software (National Institutes of Health). Where indicated, 
protein half-life was calculated using PRISM GraphPad version 7.0C (GraphPad Software, Inc). 
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2.3  RESULTS 
2.3.1   Design and characterization of a new ERAD substrate 
To investigate if membrane proteins with cytosolic folding lesions are able to exit the ER 
and be degraded by other QC machineries, I used a truncated cytosolic nucleotide-binding 
domain (NBD2*) derived from Ste6-166 as the degron (Guerriero and Brodsky, 2012; Loayza et 
al., 1998). There are multiple advantages of using NBD2*: (1) Under appropriate conditions, this 
truncated domain can be targeted to different locations, namely the cytoplasm or the ER 
membrane (Guerriero et al., 2017; Guerriero et al., 2013; Prasad et al., 2012; Preston et al., 
2018); (2) Cytoplasmic folding lesions seem to be more easily detected than lumenal and 
transmembrane domain folding lesions. Namely, while some ERAD-L substrates can exit the ER 
before being retrieved back for ER degradation (Caldwell et al., 2001; Taxis et al., 2002; Vashist 
et al., 2001), vacuole/lysosome-targeted GQC substrates bearing folding lesions in the membrane 
(Pep12(D)) and lumenal domain (Wsc1*) escape ERAD detection and are instead delivered for 
lysosomal degradation (Reggiori and Pelham, 2002; Wang and Ng, 2010); (3) NBD2* is a well-
characterized degron, which on its own is efficiently degraded by the ubiquitin proteasome 
system (Guerriero et al., 2013); (4) NBD2* possesses two putative di-acidic ER-exit motifs, 
TLEVENN and QDEILEIEMYD, which may engage COPII machinery for its ER exit 
(Watanabe and Riezman, 2004). To further facilitate substrate ER exit and minimize ER 
retention, I chose a single-pass transmembrane domain from a yeast plasma membrane protein 
(Wsc1), and a triple-HA tag as the only lumenal portion of the protein.  In parallel, a “wild-type” 
version of our substrate, SZ, which instead deposits full length NBD2 in the cytoplasm and is 
similarly attached to the single-pass transmembrane domain, was also designed. (Figure 4A). 
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Figure 4 Characterization of a novel ERAD substrate 
(A) Domain schematics of SZ and SZ* (SS: signal sequence of Kar2; 3HA: triple HA tag; TMD: 
transmembrane domain; NBD2: full-length nucleotide binding domain 2 from Ste6p; NBD2*: truncated 
NBD2 from Ste6-166). (B) Microsomes from wild-type (BY4742) yeast containing SZ* or SZ were 
treated with or without 0.1M sodium carbonate and protein residence in the supernatant (S) and pellet (P) 
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fractions was analyzed after centrifugation (100,000g for 30 min) and immunoblotting (G6PD: soluble 
protein marker; Pma1: membrane protein marker). (C) Microsomes from wild-type yeast containing SZ* 
or SZ were treated with proteinase K in the presence or absence of Triton X-100 and protein remaining in 
the microsomes was analyzed by immunoblotting with anti-HA antibody. (D) Predicted topology of SZ 
and SZ*. Closed circle indicates the truncation position in SZ*. The Walker A and Walker B motifs are 
indicated as two small boxes, and the HA epitope is depicted as a triangle.  (E) The stabilities of SZ and 
SZ* were measured by cycloheximide chase analysis. Data represent the means ±SE of three to six 
independent experiments; * denotes p<0.05. 
 
Carbonate extraction assay was conducted to first confirm that SZ and SZ* are integral 
membrane proteins. After treatment, both SZ and SZ* resided in the pellet with the integral 
membrane protein marker Pma1 (Figure 4B). In contrast, the cytosolic enzyme G6PD localized 
almost completely in the supernatant. I next determined the membrane topology of SZ* and SZ 
using a protease accessibility assay. Treatment of ER enriched microsomes with limiting 
concentrations of proteinase K led to the generation of a ~7KDa peptide, corresponding to the 
expected size of the protease inaccessible triple HA tag and the appended TMD (Figure 4C). In 
addition, both SZ* and SZ migrated at their expected molecular masses (35KDa and 39KDa, 
respectively), suggesting that the four cryptic glycosylation sites in NBD2 failed to enter the ER 
(Figure 4C). Therefore, I concluded that both SZ* and SZ are type-I membrane proteins with 
NBD2 facing to the cytoplasmic side of the ER and triple HA tag deposited in the lumen (Figure 
4D).  
The stabilities of SZ* and SZ were next determined by a cycloheximide chase assay in a 
wild-type yeast strain. Similar to what was found for its cytosolic counterpart, NBD2* and 
NBD2, respectively, SZ* is highly unstable with a half-life of ~3.8 min, whereas SZ is stable and 
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possesses a half-life of ~44 min (Figure 4E). These data indicate that the truncated NBD2 targets 
SZ* for rapid degradation. 
2.3.2  SZ* is partially selected by ERAD 
Since NBD2* on its own is degraded by the UPS pathway, I hypothesized that when 
tethered to the ER membrane, SZ*, would employ the ERAD-C pathway. Four lines of evidence 
support this conclusion: First, in yeast lacking the multi-drug pump Pdr5, SZ* was stabilized 
when the proteasome inhibitor MG132 was added (Figure 5A). In contrast, SZ was relatively 
stable regardless of MG132 treatment (Figure 5B). Second, degradation of SZ* was slowed upon 
incubation at the non-permissive temperature in the cdc48-2 background (Figure 6A). Third, 
deleting the ERAD-C specific E3 ligase, Doa10, resulted in less efficient degradation of SZ* 
(Figure 6B). And fourth, mutations in either the cytosolic Hsp70, Ssa1, or Hsp40, Ydj1, reduced 
the rate of SZ* degradation (Figure 6C and 6D). In contrast, the ER lumenal Hsp70, Kar2, was 
dispensable for SZ* turnover (Figure 6E). The subcellular localization of SZ* was then 
determined by indirect immunofluorescence microscopy. In the pdr5Δ strain without treatment, 
SZ* co-localized with the ER-resident protein Kar2, which is consistent with the protein being 
targeted for ERAD (Figure 7A). Of note, SZ* was stabilized to a similar extent in each of the 
ERAD defective mutants, but was never completely stabilized. These data suggested that SZ* 




Figure 5 Proteasome dependence of SZ and SZ* 
The stabilities of SZ* (A) and SZ* (B) in the pdr5Δ strain was measured by cycloheximide chase assay 
when proteasome was inhibited with 100μM MG132 Data represent the means ±SE of three independent 
experiments; * denotes p<0.05. 
2.3.3  SZ* is sorted to the vacuole for degradation after Golgi transit 
Considering the fact that SZ* is only partially degraded by ERAD and that SZ* shares a 
similar topology with canonical GQC substrate being a single-pass membrane protein, I next 
assayed whether the degradation of SZ* took place in the vacuole. To this end, I measured SZ* 
stability in a pdr5Δ mutant that also lacks Pep4, which eliminates ~90% of vacuolar protease 
activity (Ammerer et al., 1986). Even in the absence of MG132, SZ* was mostly stable, with 
about 70% remaining after 60 min (Figure 8A). The residual degradation of SZ* in the 
pep4Δpdr5Δ strain was inhibited by MG132 (Figure 8B). In line with this evidence, SZ* also 
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accumulated in the vacuolar lumen in pep4Δpdr5Δ yeast, as shown by indirect 
immunofluorescence microscopy (Figure 7B). Therefore, the majority of SZ* is delivered to the 
vacuole for degradation. 
 
 
Figure 6 SZ* is partially degraded by ERAD pathway 
The stabilities of SZ* were determined by cycloheximide chase analyses in the wild-type and indicated 
mutant strains including (A) temperature sensitive mutant of the AAA-ATPase Cdc48 (cdc48-3), (B) 
deletion mutant of the ER-associated E3 ligase, Doa10,  (C) (D) (E) temperature sensitive mutants of 
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cytosolic Hsp70, Ssa1(ssa1-45), Hsp40, Ydj1(ydj1-151), and ER lumenal Hsp70 Kar2 (kar2-1), 
respectively. Data represent means ±SE of three to six independent experiments; * denotes p<0.05.  
Generally, the vacuolar delivery of misfolded membrane proteins happens through either 
the post-ERQC or ER-phagy pathways. To test if ER-phagy directs SZ* to the vacuole, I 
measured the stability of SZ* in multiple autophagy-deficient yeast strains (Lipatova and Segev, 
2015). As shown in Figure 9, deletion of the selected autophagy core components did not affect 
the turnover of SZ*. Post-ERQC of SZ* was next investigated by measuring the steady-state 
level of SZ* in wild-type yeast and in strains defective for ER to Golgi transport (sec23-1 and 
ypt1-3) and intra-Golgi transport (sec7-4). In contrast to the absence of an effect of autophagy on 
SZ* degradation, the steady-state level of SZ* at the non-permissive temperature increased from 
2- to 4-fold in these mutants compared to the wild-type (Figure 10A). In a representative 
experiment, I measured the degradation kinetics of SZ* in the sec23-1 background at the non-
permissive temperature, and measured the half-lives in the wild-type versus sec23-1 mutant 
strains as ~3.3 min and ~25 min, respectively (Figure 10B). Overall, these data suggest that SZ* 
is sorted into the vacuole for degradation after Golgi transit, and is therefore a substrate for both 
ERAD and post-ERQC. 
2.3.4  SZ* transport to the vacuole requires the MVB pathway 
The post-ERQC of membrane proteins, which includes GQC and plasma membrane QC, 
requires the MVB pathway for vacuolar delivery, during which ESCRT is indispensable for 
MVB biogenesis (Henne et al., 2013). Therefore, I next tested if the vacuolar delivery of SZ* 
was compromised when distinct ESCRT subunits were individually deleted. Due to concern that  
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Figure 7 Subcellular localization of SZ* in pdr5Δ and pep4Δpdr5Δ 
The subcellular localization of SZ* was determined in pdr5Δ (A) and pep4Δpdr5Δ (B) by indirect 
immunofluorescence microscopy. SZ*, ER, and the nucleus were detected with anti-HA antibody, anti-
Kar2 antiserum, and DAPI, respectively. Arrowhead in (A) denotes the ER. Arrowheads in (B) denote the 
lobes of the vacuole and the whole vacuole. Scale bar: 5μm. 
 
the lumenal HA epitope in SZ* would be degraded by vacuolar proteases, a GFP-tagged SZ* 
chimera was also constructed in which the vacuolar protease-resistant GFP moiety resides in the 
cytosol (Figure 11A). I first tested if GFP-tagged SZ* is degraded in a similar manner as HA-
tagged SZ*. Cycloheximide chase data showed that GFP-tagged SZ* behaved similarly to the 
HA-tagged version in that both substrates remained susceptible to ERAD (specifically, the 
protein remained partially dependent on Doa10) and vacuolar degradation (Figure 12A). I next 
monitored GFP cleavage of SZ* in both wild-type and ESCRT several ESCRT mutants, 
including vps27Δ (ESCRT-0), vps23Δ (ESCRT-I), vps36Δ (ESCRT-II), snf7Δ (ESCRT-III), and 
vps4Δ (the AAA-ATPase required for ESCRT recycling). At steady state, cleavage of SZ* was 
evident in wild-type yeast but absent in the ESCRT mutants (Figure 11B). As expected, the  
steady-state level of the full length species of SZ* was higher in the ESCRT mutants than in 
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wild-type background. Furthermore, live cell imaging of GFP-tagged SZ* showed that instead of 
vacuolar lumenal localization in wild-type yeast, SZ* mislocalized in the pre-vacuolar 
compartment in vps27Δ cells (Figure 11C). Consequently, SZ* is sorted into the vacuole through 
the MVB pathway. 
 
 
Figure 8 SZ* is mostly degraded in the vacuole 
The stability of SZ* was determined by cycloheximide chase analysis in PEP4pdr5Δ and pep4Δpdr5Δ 
cells in the absence (A) and presence (B) of proteasome inhibition. Data represent means ±SE of three to 
six independent experiments; * denotes p<0.05.  
 
Because plasma membrane localization of SZ* was undetectable by either indirect 
immunofluorescence or live cell fluorescence microscopy (Figure 7A, 7B and 11C), I 
hypothesized that SZ* is directed to the vacuole directly from the Golgi, but not after 
endocytosis from the plasma membrane. Because End3 coordinates assembly of the cortical actin  
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Figure 9 SZ* is not degraded though ER-phagy pathway 
The stability of SZ* in wild-type and the indicated autophagy defective mutants was determined by 
cycloheximide chase analysis. Data represent means ±SE of three independent experiments. 
 
cytoskeleton, and therefore the absence of this protein leads to defects in actin-dependent 
endocytosis (Benedetti et al., 1994), I assessed the degradation of SZ* in the end3Δ mutant strain 
after a temperature shift to 37°C. I found that deletion of END3 had no effect on SZ* degradation 
(Figure 12B). Therefore, these data suggest that the population of SZ* that escapes ERAD is 
sorted directly from the Golgi to the vacuole through an MVB intermediate.  
2.3.5  Heat stress increases ERAD targeting of SZ* by inducing its aggregation 
Multiple protein degradation pathways within the cell including ERAD, GQC and ER-
phagy are differentially affected by stress (Liu and Chang, 2008; Reggiori and Pelham, 2002; 
Schuck et al., 2014; Travers et al., 2000). To examine if SZ* targeting for either ERAD or 
vacuolar degradation is modified by exogenous stress, I first investigated whether a specific 
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stress would lead to the preferential degradation of SZ* via ERAD. Cells expressing SZ* were 
treated with a variety of stressors including ER stress, heat stress, heavy metal stress, oxidative 
stress, cell wall stress, and protein misfolding stress. Next, ERAD dependence was assayed after 
treating pdr5 cells with either DMSO (the vehicle) or MG132. Strikingly, among these 
conditions, only heat-stress significantly increased the relative fold change of SZ* stabilized by 
MG132 compared to the control (Figure 13A and 13B). The effect of heat-stress on ERAD of 
SZ* was further tested by cycloheximide chase assay (Figure 13C). Upon MG132 treatment, 
SZ* half-life was prolonged from ~34 min at 26°C to >60 min at 37°C (Figure 13D).  
 
 
Figure 10 SZ* advances to the Golgi before vacuolar degradation 
(A) The fold-change in steady-state levels of SZ* in wild-type and mutant yeast defective in ER-Golgi 
transport or intra-Golgi trafficking was examined by immunoblotting. (B) Cycloheximide chase analyses 
in SEC23 and sec23-1 cells were performed, and data represent three independent experiments; * denotes 





Figure 11 SZ* is delivered to the vacuole by way of MVB pathway 
(A) Predicted topology of GFP-tagged SZ*.  The cytosolic residence of GFP allows for analysis of MVB 
delivery to the vacuole. (B) GFP cleavage from GFP-SZ* in the wild-type and indicated mutant strains 
was determined by immunoblotting. G6PD serves as a loading control. (C) The cellular localization of 
SZ* in both wild-type and vps27Δ cells was determined by fluorescence microscopy. FM4-64 marks the 
vacuolar membrane. Arrowheads denote the lobes of the vacuole and the pre-vacuolar compartment 
(bottom). Scale bar: 5μm. 
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The effect of heat stress on SZ* degradation might have arisen from a general stress 
response, such as the heat-shock response (HSR), or from a temperature-dependent change in 
protein conformation. To examine whether HSR induction increased ERAD targeting of SZ*, I 
introduced a constitutively active heat shock factor 1 (Hsf1) mutant, Hsf1-R206S, into SZ*-
expressing yeast (Sewell et al., 1995). The introduction of this mutant permits HSR activation in 
the absence of a temperature shift, thus uncoupling the HSR from a potential heat-induced 
protein conformational change. This allows us to differentiate whether the HSR versus a direct 
increase in temperature magnified SZ* targeting for ERAD. I first measured HSR induction in 
yeast expressing Hsf1-R206S at 26°C and found that the HSR was induced to an even greater 
extent than that produced by heat shock (Figure 14A). Nevertheless, Hsf1-R206S failed to 
enhance the ERAD of SZ*, as established in either a steady-state or cycloheximide chase assay 
(Figure 14B and 14C). This finding suggests that the temperature shift instead altered the 
conformation of SZ*. 
Based on a homology model of NBD2, the truncation site in NBD2* resides between two 
beta sheets, which may lead to the generation of an aggregation-prone protein (Preston et al., 
2018). Therefore, I surmised that heat stress induces SZ* aggregation, which in turn increases 
ERAD targeting. To test this hypothesis, I conducted detergent solubilization experiment and 
measured detergent solubility under different stress conditions. Briefly, SZ*-expressing yeast 
were used to prepare ER-derived microsomes, which were then pre-treated at either 26°C or 
37°C before dodecyl maltoside (DDM) solubilization. Samples after DDM extraction were 
subject to centrifugation to separate the detergent soluble fraction. As shown in Figure 15A, the 
DDM solubility of SZ* was significantly reduced when microsomes were pre-treated at 37°C 
compared to the 26°C group. As a control, I tested whether Wsc1*, which is targeted for GQC, 
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was also subject to heat-induced aggregation in vitro.  In contrast to SZ*, DDM solubility of 
Wsc1* remain unchanged at either treatment. Furthermore, Wsc1* was not directed for ERAD 
even after heat-stress but still retained its behavior as a post-ERQC substrate, which is consistent 
with the in vitro DDM solubilization result (Figure 15B and 15C). Therefore, it seems that 




Figure 12 Endocytosis  is not involved in vacuolar delivery of SZ* 
(A) ERAD dependence of GFP tagged SZ* was assayed by cycloheximide chase in wild-type and mutant 
yeast lacking ER-resident E3 ligases HRD1 and/or DOA10. Apparent differences in degradation rate 
between the strains were not statistically significant. (B) Stability of SZ* in wild-type and an endocytosis 
defective mutant was determined by cycloheximide chase analysis. Data represent means ±SE of three 
independent experiments.  
 
To better establish a correlation between detergent solubility and ERAD targeting, I 
devised a mechanism to induce the aggregation of SZ* in the absence of a temperature shift. 
Given that protein aggregation is concentration-dependent, I next tested the effect of SZ* 
overexpression on its aggregation. A high copy number (2 plasmid under the control of a 
strong promoter (TEF promoter) was used to drive SZ* overexpression. As expected, SZ* 
overexpression led to a pronounced decrease in detergent solubility, even when the isolated 
microsomes were incubated at 26°C (Figure 15A). To further confirm that the decreased 
detergent solubility of SZ* resulted from the aggregation of its cytosolic domain, NBD2*, and 
not from another indirect effect from general protein overexpression, I tested if the aggregation 
of cytosolic NBD2* was concentration-dependent. A low and high (2 copy number NBD2* 
expression vector were introduced into yeast and cell lysates were prepared and incubated with 
sodium carbonate to liberate soluble fractions. While ~60% of NBD2* remained soluble when 
expressed at a relatively low level, overexpression of NBD2* was sufficient to reduce solubility 
by ~2-fold (Figure 15D). In line with these data, SZ*, which contains a single membrane span, 
when overexpressed was now exclusively targeted for ERAD (Figure 15E). Furthermore, 
overexpressed SZ* was retained in the ER in either the PEP4 or pep4Δ background, which is in 
contrast to its significant accumulation in the vacuole in the pep4Δ mutant when expressed at low 
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levels (Figure 15F). Because SZ* degradation under low expression conditions showed a partial 
ERAD dependence (Figure 6A), these data are consistent with a model that aggregation 
propensity is a trigger for ER retention and thus ERAD substrate selection. 
 
 
Figure 13 Heat stress increases the targeting of SZ* for ERAD 
(A) A pdr5Δ mutant strain expressing SZ* was treated with the indicated stressors for 60 min prior to the 
addition of DMSO or 100μM MG132. The level of SZ* was visualized by immunoblotting. (B) ERAD 
dependence of SZ* was quantified by the relative fold change of SZ* level treated with MG132 versus 
DMSO as in (A), and normalized to the loading control G6PD. (C) ERAD dependence of SZ* was 
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assayed by cycloheximide chase at 37°C after treatment with the proteasome inhibitor MG132 or the 
vehicle DMSO. (D) The half-life of SZ* was calculated from cycloheximide chase data. Data represent 
the means ±SE of three independent experiments. * denotes p<0.05 and ** denotes p<0.005. 
 
Figure 14 The enhanced ERAD targeting of SZ* is not caused by heat-shock response. 
(A) Heat-shock induction was measured in a reporter assay that assesses beta-galactosidase activity. (B-
C) The ERAD dependence of SZ* with constitutive HSR induction was assayed by measuring both (B) 
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steady-state levels and (C) by a cycloheximide chase assay. Data represent means ±SE of three 
independent experiments. ** denotes p<0.005 
 
It is worth mentioning that overexpression of SZ* also makes it relatively stable, 
suggesting that the ERAD-C pathway may be saturated by its overexpression or that the 
overexpression of SZ* prevents the display of the degron, thus leading to inefficient degradation. 
To examine if the secretory pathway may be saturated or compromised upon SZ* 
overexpression, I measured the degradation of a post-ERQC substrates, Wsc1*, in conjunction 
with SZ* overexpression, because Wsc1* utilizes the same transport pathway from the ER to the 
vacuole as SZ* when expressed at low levels (Wang and Ng, 2010; Wang et al., 2011c). 
However, both the half-life and the Wsc1* Golgi glycosylation pattern were similar regardless of 
whether SZ* was present or absent (Figure 15G). This evidence suggests that the post-ERQC 
pathway does not become saturated upon SZ* overexpression. Instead, I propose that SZ* 
aggregation that is induced by overexpression, even in the absence of a temperature shift, results 
in ER-retention and increased ERAD targeting.  This contrasts with the fate of an ERAD-L 
substrate, CPY*, whose overexpression still allows for ER exit and degradation in the vacuole, 
suggesting that a different ER retention mechanism exists for SZ* (Spear and Ng, 2003).  
2.3.6  Fusion of an aggregation-prone domain targets a post-ERQC substrate for ERAD 
To expand the significance of my findings, I next asked if the aggregation-prone NBD2* 
degron can act in a dominant manner to retain a post-ERQC substrate in the ER and induce 
degradation by the ERAD pathway. To answer this question, both NBD2* and the full length 
NBD2 domain were individually fused to Wsc1*, thereby generating W-N* and W-N, 
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respectively (Figure 16A).  I first examined the detergent solubility of W-N* and W-N in 
isolated membranes. Considering the fact that substrates containing NBD2* (but not NBD2) are 
targeted for proteasome-dependent degradation, and that aggregation-propensity favors ERAD 
targeting (see above), W-N* was expected to be less soluble than W-N*. As hypothesized, the 
DDM solubility of W-N* was lower than that of W-N (Figure 16B). Next, I examined the 
trafficking of these proteins in the cell. Previous work suggested that the lumenal domain of 
Wsc1* is glycosylated in the Golgi, which serves as a read-out for ER exit as the Golgi species 
migrates somewhat slower than the ER population by SDS-PAGE (Wang and Ng, 2010). As 
expected, only W-N exits the ER as shown by the presence of the slightly higher molecular 
weight species (Figure 16C; Western blot, bottom panels). In contrast, W-N* was unable to exit 
the ER since Golgi-associated glycosylation was absent (Figure 16D; Western blot, bottom 
panels). Additionally, turnover of W-N* was proteasome-dependent (Figure 16D), whereas W-N 
was relatively stable and not degraded by the proteasome (Figure 16C). To confirm these results, 
I also performed pulse chase experiments, during which glycan maturation can be clearly 
detected. In accordance with the cycloheximide chase data, only W-N* exhibited partial 
proteasome-dependent degradation (Figure 17A and 17B). Consistent with proteasomal 
dependent degradation, the ERAD-C ubiquitin ligase Doa10 was required for efficient 
degradation of W-N* but not W-N (Figure 17C and 17D). Together, these data demonstrate that 
a misfolded and aggregation-prone domain, NBD2*, is sufficient to target a post-ERQC substrate 
for ERAD. Moreover, this aggregation-prone ERAD-C determinant is dominant over the 







Figure 15 ERAD targeting of SZ* correlates with higher substrate aggretation propensity. 
(A) Microsomes from wild-type yeast expressing SZ* under the control of the TEF promoter in either a 
CEN (low) or a 2μ (high) plasmid were treated at the indicated temperature and with 1% DDM. Protein 
residing in the supernatant (S) and pellet (P) fractions was analyzed after centrifugation at 18,000g for 30 
min and immunoblotting. Sec61 was used as a control. (B) The proteasomal dependence of Wsc1* were 
assayed in steady-state levels after treatment with MG132 or DMSO at 26°C or 37°C. (C) The DDM 
solubility of Wsc1* was measured after incubation at the indicated temperature and centrifugation as in 
(A). (D) Wild-type yeast lysate containing a soluble version of SZ* that lacks a TMD (“NBD2*”) was 
treated with 100mM Na2CO3, followed by centrifugation as in part (A) and immunoblotting. (E) ERAD 
dependence of SZ* at high expression was assayed by a cycloheximide chase at 26°C after treated with 
the proteasomal inhibitor MG132 or DMSO. (F) The cellular localization of SZ* expressed at high level, 
and the position of the nucleus and ER was determined in both pdr5Δ and pep4Δ pdr5Δ cells by indirect 
immunofluorescence microscopy in the absence of proteasome inhibition. Arrowheads denote the ER. 
Scale bar: 5μm. (G) Stability of Wsc1* was determined in the presence or absence of an SZ* high copy 
expression plasmid (p426TEF) by cycloheximide chase analysis. Data represent the means ±SE of three 
independent experiments; * denotes p<0.05, and ** denotes p<0.005 
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Figure 16 Fusion of the aggregation-prone NBD2* domain targets a post-ER quality 
control substrate, Wsc1*, for ERAD 
(A) The predicted topologies of the chimeric proteins. (B) The DDM solubility of two chimeric proteins, 
W*-N and W*-N*, in ER-derived microsomes. ERAD dependence of (C) W*-N and (D) W*-N* was 
assayed by cycloheximide chase after treatment with the proteasomal inhibitor MG132 or the vehicle 
DMSO. Data represent means ±SE of three independent experiments; * denotes p<0.05. 
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2.4  DISCUSSION 
Membrane proteins are subjected to multiple PQC checkpoints along the secretory 
pathway, including ERQC, GQC, and plasma membrane QC. During ERQC, the three branches 
of ERAD, ERAD-L, -C, and –M, monitor protein folding status in different locations relative to 
the ER membrane (i.e., the lumen, cytoplasm, and membrane, respectively). It has long been 
recognized that ERAD-C substrates seem to be statically retained in the ER for ERAD.  Many 
ERAD-L substrates, however, do advance to the Golgi and are retrieved for ER degradation. In 
addition, one typical type of vacuole/lysosome-targeted GQC substrate is a single-pass 
membrane protein bearing folding lesions in the membrane domain, suggesting that ERAD-L 
may not efficiently detect folding lesions in the membrane span. A survey of vacuole-targeted 
GQC substrates showed that these substrates are mostly single-pass membrane proteins with 
folding lesions in either the lumenal or membrane domain. However, it remains unclear if 
membrane proteins with cytosolic folding lesions can be statically retained in the ER. To this 
end, I sought to investigate if membrane proteins with ERAD-C degrons are able to exit the ER 
and how ERAD-C machinery selects its substrates. This had never before been examined. 
Therefore, the first goal of this chapter was to characterize a new substrate and investigate how 
this protein was selected by ERAD-C. A novel substrate, SZ*, with well-characterized cytosolic 
degron NBD2* appended to the single-pass membrane domain of Wsc1 was constructed. 
Previous work on NBD2*, which is completely soluble, indicated that the nuclear ubiquitin 
ligase San1 targets it for proteasomal degradation (Guerriero et al., 2013; Prasad et al., 2012). 
Also, a somewhat similar construct (WS) created by the Ng lab suggested that the ER-resident 
E3 ligase Doa10 targets this protein for ERAD (Prasad et al., 2012). Here, I similarly found that 
SZ* is directed to the canonical ERAD-C pathway, as its turnover required ERAD-C-specific 
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components: Doa10 (Ubiquitin ligase), Ssa1 (cytosolic Hsp70), and Ydj1 (a cytosolic Hsp40 that 
associates with the ER). Therefore, my data first showed that the ERAD-C degron, which is 
shared with other well-characterized substrates such as Ste6* and Chimera A*, is sufficient to 
target SZ* for ERAD. My further characterization showed a surprising result: SZ* with a 
canonical ERAD-C degron also efficiently exited the ER and was directed for vacuolar 
degradation through the MVB pathway. This unexpected result not only expands the scope of 
misfolded membrane proteins that are able to escape ER retention and ERAD, but also suggests 
that misfolded membrane proteins, even with ERAD-C degrons, do have the potential of 
escaping ERAD and becoming a post-ERQC substrate.  
There are several possible explanations underlying the ER exit of SZ*. First, two putative 
di-acidic ER exit signals exist in the cytosolic domain of SZ* (TLEVENN and 
QDEILEIEMYD), which may allow a substantial fraction of the substrate to be captured by the 
COPII machinery. In line with this hypothesis, a previous study showed that when CPY* was 
fused to a functional ER exit signal, it traffics from the ER and was degraded in the vacuole 
(Kincaid and Cooper, 2007). In contrast, the ER retention of another NBD2* bearing substrate, 
Ste6*, may result from the potential interactions between NBDs that may otherwise bury the ER 
exit signal on NBD2*. Second, the transmembrane domain of SZ*, which is derived from a 
plasma membrane protein, Wsc1, may contain a sorting signal for post-ER trafficking (Rayner 
and Pelham, 1997; Singh and Mittal, 2016). The requirement of the MVB pathway for sorting 
SZ* into the vacuole indicates the involvement of protein ubiquitination at a post-ER organelle, 
either the Golgi or at the plasma membrane. By testing protein stability in an endocytosis mutant 
(end3Δ), I confirmed that SZ* is a bona fide vacuole/ lysosome -targeted GQC substrates, which 
is sorted directly from the Golgi to the vacuole through the MVB pathway. The ubiquitin ligase 
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required for the post-ER ubiquitination of SZ*, however, remains unidentified. Given the 
topology and the cytosolic folding lesions in SZ*, Rsp5 may be a good candidate to test. 
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Figure 17 Charactering the ERAD-dependence of the Wsc1*-NBD2 and Wsc1*-NBD2*  
Pulse chase analyses of chimeric proteins (A) W*-N and (B) W*-N* in the presence of the proteasomal 
inhibitor MG132 or the vehicle DMSO.  Note the appearance of a Golgi modified species that was 
significantly more apparent in W*-N (A), and the different rates in the loss of the ER form of W*-N and 
W*-N* in the presence of MG132.  ERAD dependence of (C) W*-N and (D) W*-N* was assayed by 
cycloheximide chase in wild-type and mutant yeast lacking the ER-resident E3 ligases HRD1 and/or 
DOA10. Data represent means ±SE of three independent experiments. “Hyper-G” denotes 
hyperglycosylated species. 
 
It remains elusive how ERAD cooperates with the post-ERQC machinery to safeguard 
protein homeostasis. One possibility is that ERAD retains and degrades substrates with ill-
defined ERAD-specific degrons, which reside in substrates like CPY* and Ste6-166 (Loayza et 
al., 1998; Wolf and Schafer, 2005), whereas substrates lacking the degron, such as post-ERQC 
substrates Wsc1* and Pep12 (D) exit the ER for post-ERQC. Another view is that ER-associated 
chaperones—either lumenal (BiP and lectins) or cytosolic (Ssa1 and Ydj1)—act as gatekeepers 
for ER retention and ERAD after recognition. Those substrates that simply lack these recognition 
motifs will instead exit the ER.  In fact, we previously reported that mutated forms of bovine 
pancreatic trypsin inhibitor (BPTI) that lack BiP binding sites escape ERAD and are targeted 
exclusively for vacuolar degradation (Coughlan et al., 2004). Similarly, the post-ERQC substrate 
Wsc1*, which is unable to bind BiP, was efficiently degraded in the vacuole. However, when 
attached to a BiP binding ERAD determinant, the C-terminal domain of CPY*, the chimeric 
protein was targeted for ERAD (Wang and Ng, 2010).   
SZ* contains both an ERAD-C degron (NBD2*) and engages chaperones (Ssa1 and 
Ydj1), which complicates future attempts to define how this substrate is selected for ERAD. 
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However, my results indicate that aggregation propensity may be a new feature that dictates how 
ERAD substrates might be selected. Based on a homology model, NBD2* may be intrinsically 
aggregation-prone because the truncation site lies between two hydrophobic beta-sheets that are 
otherwise buried in the full-length domain (Preston et al., 2018). I propose that the exposed 
hydrophobic patches on NBD2* drive amorphous aggregation upon heat-shock and 
overexpression. Under those conditions, the ERAD machinery may outcompete the ER exit 
machinery (i.e., COPII) (Barlowe and Helenius, 2016). In this case, substrates aggregation may 
on the one hand enhance chaperone engagement, which leads to ER retention and ERAD, but on 
the other hand, substrate aggregation in the cytosolic domain may obscure the ER exit signal that 
is already weakly presented, hindering ER exit.  
Compared to mammals, yeast possess only smaller COPII vesicles due to the lack of an 
enlargement mechanism that exists in mammals for large secretory cargo, like procollagen and 
chylomicrons (Jin et al., 2012). Therefore, SZ*, when aggregated under heat-stress or 
overexpression conditions, may also be too large to be incorporated into COPII vesicles. 
However, immunofluorescence imaging of overexpressed SZ* (Figure 15F) showed a diffusive 
ER pattern without any noticeable punctate, which doesn’t seem to support this hypothesis. 
Instead, enhanced chaperone engagement and/or less efficient ER exit may explain why 
aggregated SZ* failed to exit the ER. (An alternate mechanism for ER retention is described in 
the next chapter.) Although the nature of a misfolded region that leads to the designation for one 
QC pathway over another remains unclear, my data indicate that aggregation propensity may be 
one such feature. Correlations between ER retention (which leads to the proteasome degradation) 
and protein aggregation are also supported by previous studies in both mammals and yeast. The 
relative localization of two aquaporin (AQP)-2 mutants in mammals, T126M (ER), and E258K 
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(Golgi), correlated with detergent solubility, with T126M being less soluble than E258K (Hirano 
et al., 2003; Tamarappoo et al., 1999). In yeast, the amino acid permeases (AAPs) require an ER 
membrane-localized chaperone Shr3 for proper folding and ER export (Kota et al., 2007). In the 
absence of Shr3, AAPs become aggregated and retained in the ER for efficient clearance by 
ERAD, which provide additional evidence on the negative correlation between protein 
aggregation and ER export.    
In summary, the work in this chapter demonstrates for the first time that a single-pass 
membrane protein with an ERAD-C degron can be targeted for degradation by both ERAD and 
post-ERQC, and adds another substrate to the post-ERQC substrate toolbox (Figure 18). 
Furthermore, the aggregation state of SZ* determines the trafficking decision. Namely, substrate 
aggregation dictates degradation by ERAD over post-ERQC. In the future, it will be necessary to 
identify the machinery that leads to the selection of the substrate for degradation in the vacuole 






Figure 18 Summary of the degradation fate of misfolded membrane proteins 
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3.0  SUBSTRATE UBIQUITINATION DICTATES THE ER RETENTION OF 
MISFOLDED PROTEINS  
3.1  INTRODUCTION 
Secretory or membrane proteins first begin their journey along the secretory pathway at 
the ER. After newly synthesized proteins reach their native conformation and assemble into 
multi-subunit complexes with defined stoichiometry, they concentrate in COPII vesicles for ER 
export (Barlowe and Helenius, 2016). During this process, cargo receptors for lumenal (e.g., 
Evr29) and membrane (e.g., Sec24) cargos recognize transport-competent proteins and recruit 
the outer layer Sec13/31 heterotetramer of the COPII coat. Polymerization of the COPII coat 
proteins forms a cage-like lattice which then drives ER cargo export (Stagg et al., 2006). COPII-
mediated anterograde transport is vital for cellular homeostasis and survival as most genes 
involved in COPII transport are essential, and mutations in those genes have been found to cause 
human diseases such as Anderson disease, chylomicron retention disorder, and cranio-lenticulo-
sutural-dysplasia (Khoriaty et al., 2012).  
Due to genetic mutations, environmental stress such as heat shock, oxidative stress, 
heavy metal stress, and aging, protein misfolding becomes more common (Gidalevitz et al., 
2011). Due to genetic mutations, a growing number of human diseases are also attributed to 
protein misfolding, especially those in the secretory pathway (Guerriero and Brodsky, 2012; 
Labbadia and Morimoto, 2015; Tao and Conn, 2014). To maintain protein homeostasis, multiple 
protein QC machineries along the secretory pathway are employed. The first QC checkpoint is 
ERAD. As described in detail in the previous chapters, ERAD employs the protein-ubiquitin 
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system to selectively eliminate proteins that are terminally misfolded, thereby preventing 
misfolded proteins from moving further along the secretory pathway. However, some proteins 
that are degraded by ERAD can also fold and function when cells are treated with folding 
“correctors”, some of which are now FDA-approved (Rowe and Verkman, 2013). If the ERAD 
of those proteins is slowed, then the efficiency of these correctors is improved (Chung et al., 
2016; Di et al., 2016; Penchala et al., 2013). Therefore, rescuing these proteins from ERAD and 
facilitating their ER exit can serve as a promising strategy for treatment of some human diseases.  
The ability to rescue ERAD substrates is facilitated by the fact that many are poorly 
retained in the ER, which favors forward trafficking. In yeast, some ERAD-L substrates (such as 
CPY* and PrA*) exit the ER through COPII vesicle transport and are then retrieved for ER 
degradation (Caldwell et al., 2001; Taxis et al., 2002; Vashist et al., 2001). Subsequent studies 
showed that transport-defective CPY* is still efficiently eliminated by ERAD, suggesting that 
ER exit and ERAD are not sequential steps but competitive process (Kawaguchi et al., 2010; 
Spear and Ng, 2003). However, the molecular mechanism behind competition is unclear.  
In this chapter, I aimed to understand how ERAD competes with the ER export 
machinery for substrates that display a functional ER exit signal. To this end, SZ*, which was 
described in the previous chapter, was used as a model. I first discovered that the cytosolic 
Hsp40, Ydj1, selectively recognizes and retains SZ* in the ER. Specifically, overexpression of 
Ydj1 leads to enhanced ERAD of SZ*, whereas deletion of YDJ1 results in more efficient ER 
export. I then found that deletion of the gene encoding the ERAD-C ubiquitin ligase, Doa10, 
leads to more efficient ER export both in vivo and in vitro. This result strongly suggested that 
substrate ubiquitination may be a hallmark for ER retention and the prevention of ER export. To 
confirm this hypothesis, I fused SZ* with a four-tandem ubiquitin motif and assayed ER export 
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both in vivo and in vitro. As hoped, the ubiquitin-fused SZ* chimera was retained in the ER. 
Retention was evident even in a doa10Δ strain, which otherwise favored export of SZ*. 
Moreover, I found that Ydj1 was vital for SZ* ubiquitination, consistent with its role as a 
gatekeeper for a misfolded substrate. Overall, these data provide the first mechanistic evidence 
that ubiquitin can act as a hallmark for substrate retention in the ER, irrespective of the presence 
of a functional ER exit signal. 
3.2  MATERIALS AND METHODS 
Most of the materials and methods that used in this chapter remained the same as 
described in section 2.2. Therefore, only additional experimental methods that are specific to this 
chapter are listed. 
3.2.1   Yeast growth conditions, strains, and plasmid construction 
The Saccharomyces cerevisiae strains employed in this chapter are provided in Table 1. 
Yeast growth conditions and media remained the same as described in section 2.2.1.  
To construct SZ*-Ub4, the BamHI restriction site on pSZ03 bearing SZ*-GFP was 
altered by site-directed mutagenesis (Quick-change site-directed mutagenesis kit, Agilent) using 
primers OSZ14 and OSZ15 (all primers used in this chapter was listed in Table 3). The SZ*-GFP 
insert was next PCR amplified using primers OSZ08 and OSZ16, and subcloned into the 
p416TEF vector at the XbaI/BamHI sites, generating pSZ09 (Mumberg et al., 1995). Next, a 
gene cassette encoding four ubiquitin moieties with K48, K63 and K29 mutated to R (plasmid 
 85 
1677, kindly provided from the Ulrich lab, University of Mainz, Germany) was inserted into the 
C-terminus of SZ*-GFP (pSZ09) at the BamHI/HindIII sites, thus generating pSZ10 (Zhao and 
Ulrich, 2010).  
The Ydj1-HPD mutant (pSZ12) was constructed by site-directed mutagenesis using 
template BPM390 (kindly provided by the Craig lab, University of Wisconsin) and primers 
OSZ17 and OSZ18. The DNA sequences of all constructs were confirmed by Genewiz. 
3.2.2  Assays to measure protein ubiquitination 
To measure the levels of protein ubiquitination in yeast, a 30ml culture of the indicated 
yeast strains expressing SZ*, SZ*-Ub4 or Wsc1* was grown to an A600 of ~1.0 in selective 
media at 26°C or 37°C (as indicated). Yeast cells were harvested by centrifugation at 3000rpm 
for 3 min in tabletop centrifuge at room temperature, and then washed with ice-cold buffer 88, 
and the cell pellets were frozen at -80°C. The cells were then thawed on ice, and resuspended in 
a microcentrifuge tube with 1ml of a detergent solution containing 20mM HEPES (pH=7.4), 
50mM KOAc, 2mM EDTA, 0.1M sorbitol, 1% Triton X-100, 0.2% SDS, and protease inhibitors 
(1mM PMSF, 0.5μg/ml pepstatin A, and 1μg/ml leupeptin), and supplemented with 10mM N-
ethylmaleimide. Next, the yeast cells were disrupted with small glass beads by agitation on a 
Vortex mixer (1 min for 6 times with 1 min on ice in between each agitation). Unbroken cells, 
cell debris, and insoluble material was removed using a tabletop centrifuge at 18,000g for 3 min 
at 4°C. Target proteins were immunoprecipitated overnight at 4°C with 30μl of anti-HA-
conjugated beads (Roche Applied Science), and the next day HA beads were pelleted using a 
tabletop centrifugation for 1min at 700g at 4°C. The beads were then washed three times with the 
detergent solution, one time with 2M urea in the detergent solution, and one final wash with the 
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detergent solution. Precipitated proteins were eluted with 25μl TCA sample buffer for 30 min at 
37°C, and then resolved on 10% SDS-PAGE followed by western blotting. Poly-ubiquitin was 
visualized using anti-ubiquitin antibody (P4D1 from Santa Cruz Biotechnology).  
3.2.3  Assays to measure protein budding efficiency 
An in vitro COPII budding assay was performed as previously described (Barlowe et al., 
1994). Briefly, five components of the COPII complex, including Sar1, Sec23/24, and Sec13/31 
were first purified using plasmid CBB205, yeast CBY1285, and yeast CBY120, respectively 
based on the protocol described previously (Barlowe et al., 1994). Plasmid CBB205, yeast 
CBY1285 and CBY120 are kind gifts from Dr. Charles Barlowe (Dartmouth College). The 
COPII proteins were then added to ER microsomes expressing SZ* from different yeast strains 
to the final indicated concentrations: microsomes (40μg/ml), Sar1 (5μg/ml), Sec23/24 (5μg/ml), 
and Sec13/31 (12μg/ml). The reaction was conducted in PCR tubes incubated at 25°C for 20 min 
in a mini PCR cycler. The budded vesicles were then separated from total ER membranes by 
centrifugation at 18,000g at 4°C in a tabletop centrifuge. The budded vesicles residing in the 
supernatant were then pelleted by a second centrifugation at 100,000g for 20 min at 4°C in a 
Beckman ultracentrifuge. The resulting budded and unbudded fractions were resuspended in 
10μl TCA sample buffer and heated at 75°C. Samples were then resolved on 10% SDS-PAGE 
and immunoblotted for the indicated proteins.  
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3.3  RESULTS 
3.3.1  The cytosolic Hsp40, Ydj1, recognizes and targets SZ* for ERAD  
I demonstrated in the previous chapter that SZ*, which contains an ERAD-C degron, 
partially evades ERAD and becomes a vacuole/lysosome-targeted GQC substrate, and that 
substrate aggregation changed the balance between SZ* ERAD and post-ERQC (Sun and 
Brodsky, 2018). However, protein aggregation may not be a common feature of all ERAD-C 
substrates that are retained in the ER. Here, I sought to identify whether other features of this 
substrate designate ERAD over post-ERQC. Toward this goal, I first focused on identifying 
factors that selectively recognize and mediate the ERAD of SZ*. 
The ERAD pathway takes place in four steps: substrate recognition, ubiquitination, 
retrotranslocation, and proteasome degradation (Needham et al., 2019). During the recognition 
step, ERAD substrates with an exposed signal or folding lesion are captured and bound by 
molecular chaperones, which then deliver substrates to the ubiquitination machinery (Berner et 
al., 2018; Christianson and Ye, 2014; Ruggiano et al., 2014). In the previous chapter, the 
cytosolic Hsp40, Ydj1, was shown to facilitate the ERAD of SZ*.  In contrast to a temperature 
sensitive mutant form of Ydj1, ydj1-151, which was used in the previous chapter, a YDJ1 null 
mutant was employed to avoid artifacts associated with heat stress-induced aggregation (Sun and 
Brodsky, 2018). Consistent with data generated in ydj1-151, SZ* was also stabilized in a ydj1Δ 
strain (Figure 19A). During the degradation of other ERAD-C substrates, Ydj1 has been shown 
to play an important role in mediating substrate ubiquitination (Lee et al., 1996; Prasad et al., 
2018). To test whether Ydj1 was also required for SZ* ubiquitination, the protein was 




Figure 19 The cytosolic Hsp40, Ydj1, mediates the ubiquitination of SZ* and targets it for 
ERAD 
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(A) The stability of SZ* in wild-type and ydj1Δ mutant was determined by a cycloheximide chase assay 
at 26°C. (B) SZ* ubiquitination was detected in wild-type and ydj1Δ yeast grown at 26°C to the log phase 
and then shifted to 37°C or 26°C for 30 min. Cells were lysed and SZ* was immunoprecipitated using 
anti-HA-conjugated agarose beads. Total ubiquitin and SZ* were detected using anti-ubiquitin antibody 
(P4D1 from Santa Cruz Biotechnology) and HA antibody (Roche), respectively. (C) Quantification of the 
data shown in part (B). (D) The stability of a post-ERQC substrate, Wsc1*, in wild-type and ydj1Δ was 
determined by a cycloheximide chase assay in cells grown at 26°C. (E) The ubiquitination of Wsc1* was 
detected as described in (B). (F) Quantification of the data shown in part (E). (G) Proteasome dependent 
degradation was measured by cycloheximide chase assay in pdr5Δ yeast containing either a vector control 
or a vector engineered for the expression of Ydj1 (Ydj1OE). Cells were incubated at 26°C and 100μM 
MG132 or DMSO was added for 30 min before cycloheximide addition. Data represent the means ± SE 
of three independent experiments; * p<0.05, ** P<0.005, *** P<0.0005. 
 
was poly-ubiquitinated in the wild-type strain, whereas the ubiquitination on SZ* was essentially 
abolished upon YDJ1 deletion in cells grown at 26°C (Figure 19B). Furthermore, enhanced 
ERAD targeting of SZ* after cells were shifted to 37°C (Figure 13C) correlated with a higher 
level of SZ* ubiquitination, which was also dependent on Ydj1. As a control for these studies, I 
tested whether a post-ERQC substrate, Wsc1*, was also subject to Ydj1-mediated ubiquitination 
and degradation. In contrast to data with SZ*, Ydj1 was dispensable for Wsc1* ubiquitination or 
degradation (Figure 19D and 19E). Based on these results, I next reasoned that overexpression of 
Ydj1 may increase SZ* ERAD. As hypothesized, the degree of SZ* stabilization in the presence 
of the proteasome inhibitor MG132 was even higher after Ydj1 overexpression, consistent with 
Ydj1-mediated targeting of SZ* ERAD (Figure 19G). These data indicate that Ydj1 is required 
for SZ* ubiquitination and subsequent ERAD.  
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3.3.2  Loss of Ydj1 facilitates the ER export of SZ* 
Because SZ* can also be targeted for post-ERQC (Sun and Brodsky, 2018), I next tested 
if the loss of Ydj1 affected ER exit. The ER export of SZ* can be monitored by the generation of 
a free, stable GFP moiety that results from vacuolar delivery of SZ*-GFP. As shown in Figure 
20A, loss of YDJ1 resulted in a higher level of the cleaved GFP moiety, indicating that the 
population that exited the ER and was sorted into the vacuole rose when this chaperone was 
absent. To determine whether only Ydj1 affected SZ* degradation and trafficking, I tested 
another ER-associated Hsp40, Hlj1, which is dispensable for SZ* ERAD. Consistent with the 
lack of an effect of Hlj1 on the ERAD of SZ*, Hlj1 had no effect on SZ* trafficking, as indicated 
by the similar amount of cleaved GFP in hlj1Δ and wild-type strains (Figure 20A). Because Ydj1  
recruits Rsp5 through a PPXY motif to clear heat stress damaged proteins (Fang et al., 2014). I 
examined if the PPXY motif in Ydj1 is required to retain SZ* in the ER, even though these 
studies were conducted at 26°C. Therefore, Ydj1*, with a PPXY motif mutated to GGXY, was 
then introduced into the ydj1Δ strain (Fang et al., 2014). Similar to what was found in the wild-
type strain, GFP cleavage was low, so the PPXY motif is dispensable for Ydj1 function during 
ER retention (Figure 20B). To determine if Ydj1 acts as an ERAD gatekeeper, GFP cleavage of 
SZ* was tested upon Ydj1 overexpression. In line with the cycloheximide chase data (Figure 
19G), Ydj1 overexpression enhanced SZ* ER retention as shown by less GFP cleavage 




Figure 20 Loss of Ydj1 facilitates the ER exit of SZ* 
(A) GFP cleavage from SZ*-GFP was assayed in a yeast strain lacking Ydj1 or another ER-associated 
Hsp40 and Hlj1. Cells expressing SZ*-GFP were grown to log phase at 22°C and 1OD of cells were 
collected and proteins were precipitated to detect both the full-length SZ* and cleaved GFP. (B) GFP 
cleavage from SZ*-GFP was assayed in yeast deleted for YDJ1 but that contained a vector control, or 
vectors engineered for the expression of Ydj1 or Ydj1*, which contained a mutation in the PPXY motif in 
the C-terminal tail. (C) Decreased levels of GFP cleavage from SZ*-GFP are evident in yeast expressing 
elevated level of Ydj1. Cells expressing SZ*-GFP but deleted for (-), expressing normal levels (+), or 
expressing elevated levels (++) of Ydj1 were grown to log phase at 26°C and 1OD of cells were collected 
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and proteins were precipitated to detect both the full-length SZ* and cleaved GFP. (D) A schematic of the 
in vitro ER exit/budding assay, which was used to measure COPII-mediated export of SZ* from the ER. 
(E) An in vitro COPII budding assay was performed with microsomes prepared from wild-type and ydj1Δ 
yeast expressing SZ*. In the experimental group, microsomes, enriched COPII proteins, GTP and an 
ATP-regenerating system (ATP-RS) were incubated in buffer for 25 min at 25°C. The control experiment 
was conducted in the absence of COPII proteins and energy. Unbudded membranes (M) reside in the 
pellet after centrifugation at 18,000. The budded vesicles (V) in the supernatant were collected after 
ultracentrifugation.  Data are representative of three independent experiments. 
 
To confirm the hypothesis that Ydj1 helps retain SZ* in the ER, I next conducted an in 
vitro budding assay using purified COPII components and ER-enriched microsomes from YDJ1 
and ydj1Δ yeast expressing SZ*-GFP (Figure 20D). Briefly, microsomes were prepared as 
described in the previous chapter, and the purified COPII components, including Sar1, Sec23/24, 
and Sec13/31, were isolated as published (Barlowe et al., 1994). These reagents were then mixed 
in the presence or absence of ATP/GTP or in the presence or absence of COPII (Figure 20E). In 
this assay, proteins that exit the ER in COPII vesicles will reside in the budded vesicles, which 
are separated from unbudded ER membranes by centrifugation. In line with the GFP cleavage 
experiment in Figure 19, loss of Ydj1 promoted ER export of SZ. Of note, because the in vitro 
budding efficiency is low, the amount of exported SZ* is barely detectable in the wild-type 
background (Barlowe et al., 1994). These data suggest that other auxiliary factors that may be 
excluded in the in vitro system support ER export of SZ*. Regardless, both my in vivo and in 
vitro data indicate that Ydj1 helps retain an ERAD substrate in the ER.  
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3.3.3  Defects in SZ* ubiquitination facilitate ER exit 
 As an Hsp40 co-chaperone for Hsp70 and other chaperones, Ydj1 plays two roles during 
ERAD: maintaining substrate solubility and mediating substrate ubiquitination (Lee et al., 1996; 
Nishikawa et al., 2005; Prasad et al., 2018). Because SZ* is aggregation-prone, particularly at 
elevated temperatures, I measured SZ* solubility in DDM in the presence or absence of Ydj1 
(Sun and Brodsky, 2018). As shown in Figure 21A, SZ* became less soluble in detergent-treated 
lysates from ydj1Δ cells. Because substrate aggregation can favor the selection of membrane 
proteins for ERAD, the loss of the Ydj1 could instead favor—not prevent (via facilitated ER 
exit)—ERAD (Preston et al., 2018; Sun and Brodsky, 2018). These dual functions of Ydj1 
during ERAD seem contradictory. To better explore how Ydj1 retains SZ* in the ER, and 
supports substrate ubiquitination and degradation, I explored whether Hsp70 interaction was 
required for these functions. The HPD motif on Ydj1 is required to activate the ATPase activity 
of Hsp70, which together are required to prevent substrate aggregation (Mayer and Bukau, 2005; 
Nishikawa et al., 2005; Tsai and Douglas, 1996). Therefore, I tested whether mutating the HPD 
motif would block substrate ubiquitination, which may phenocopy the loss of Ydj1 during 
ERAD. To this end, I first measured the stability of SZ* in a ydj1Δ strain containing either a 
vector, wild-type Ydj1, or the Ydj1-HPD mutant, respectively. As shown in Figure 21B, cells 
expressing the HPD mutant stabilized SZ* to a similar extent as those containing the vector 
control, suggesting that the HPD motif—and by definition, Hsp70 (Ssa1) interaction—is 
required to efficiently degrade SZ*. As expected, cells expressing the Ydj1-HPD mutant also 
exhibited compromised SZ* ubiquitination, which was similar to the effects observed in Ydj1 
null mutants (Figure 21C and 21D). Moreover, in line with evidence presented above, ER export 
of SZ* was more efficient in the Ydj1-HPD mutant than in wild-type cells, as evidenced by 
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increased GFP cleavage (Figure 21E). Therefore, cells expressing the Ydj1-HPD mutant protein, 
which is defective for substrate ubiquitination, also display increased ER exit of SZ*, similar to 
the Ydj1 null mutant. Next, the DDM solubility of SZ* was measured in cells expressing the 
Ydj1-HPD mutant. The solubility of SZ* was also decreased in this strain to a similar extent as 
in the Ydj1 null mutant. These results suggest that Ydj1 maintenance of substrate solubility and 
substrate ubiquitination are coupled, as shown for the effects of other chaperone during ERAD 





Figure 21 Defects in SZ*ubiquitination by mutating HPD motif of Ydj1 facilitate ER 
exit 
(A) Microsomes from ydj1Δ expressing SZ* and containing a vector or expressing Ydj1 or the QAA 
(HPD) mutant were treated with 1% dodecyl maltoside (DDM). Protein residing in the supernatant (S) 
and pellet (P) fractions was analyzed after centrifugation at 18,000g for 30 min. (B) The stability of SZ* 
was determined by cycloheximide chase assay in ydj1Δ yeast containing a vector control (+vector) or a 
vector engineered for the expression of wild-type Ydj1 (+Ydj1) or the Ydj1-HPD mutant (+QAA). (C) 
SZ* ubiquitination was detected in ydj1Δ yeast containing a vector control (+vector) or a vector 
engineered for the expression of wild-type Ydj1 (+Ydj1) or the Ydj1-HPD mutant (+QAA). Cells were 
grown at 26°C to log phase and lysed, and SZ* was immunoprecipitated using anti-HA-conjugated 
agarose beads. Total ubiquitin and SZ* were detected using anti-ubiquitin antibody (P4D1 from Santa 
Cruz Biotechnology) and HA antibody (Roche), respectively. (D) Quantification of (C). (E) GFP cleavage 
from SZ*-GFP was assayed in ydj1Δ yeast containing a vector control (+vector) or a vector engineered 
for the expression of wild-type Ydj1 (+Ydj1) or the Ydj1-HPD mutant (+QAA). As a control, GFP 
cleavage from SZ*-GFP was also tested in wild-type yeast containing a vector. Data represents means ± 
SE of three independent experiments; * p<0.05, ** P<0.005, *** P<0.0005. 
 
3.3.4  Defects in SZ* ubiquitination by deletion of an E3 ligase also promote ER export 
Based on the data presented above, I propose that ER retention of SZ* is determined 
either by substrate ubiquitination alone, which is facilitated by Ydj1, or by the maintenance of 
solubility and ubiquitination. To distinguish between these two possibilities, I next focused on 
the action of the ubiquitination ligase, Doa10, which functions downstream of Ydj1 during SZ* 
ERAD.  
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Doa10 was shown in the previous chapter to facilitate SZ* degradation (Figure 6B). To 
directly measure if Doa10 is required for substrate ubiquitination, I measured SZ* ubiquitination 
in the presence and absence of Doa10. In this experiment, SZ* was expressed in both wild-type 
and doa10Δ yeast at 26°C. After cell lysis, SZ* was immunoprecipitated under denaturing 
conditions, and the ubiquitination of SZ* was detected by western blot (Figure 22A and 22B). As 
predicted, ubiquitination of SZ* was reduced in the doa10∆ strain. Therefore, by examining the 
ER exit and solubility of SZ* in the presence or absence of Doa10, one could establish if 
ubiquitination is required for ER retention. I measured the cleavage and stability of GFP from 
SZ*-GFP in the DOA10 and doa10Δ strains. As shown in Figure 22C, higher levels of cleaved 
GFP accumulated in the doa10Δ strain, indicating that more SZ* exited the ER. In parallel, 
cleaved GFP accumulated in the vacuole (indicating the population of SZ* that had exited the 
ER), as suggested by immunofluorescence microscopy (Figure 22D and 22E). Consistent with 
GFP cleavage data, imaging quantification showed higher level of vacuolar GFP signal in both 
doa10Δ and ydj1Δ yeast compared to the wild-type strain. Next, to measure the kinetics of GFP 
cleavage, I performed a pulse-chase assay. As shown in Figure 22F, cleaved GFP was generated 
at a much higher rate in the doa10Δ strain within the 60 min chase period. These data 




Figure 22 Decreased ubiquitination of SZ* by deleting DOA10 facilitate ER exit 
(A) Wild-type and doa10Δ cells expressing SZ* were grown at 26°C to log phase, the ubiquitination of 
SZ* was detected after cell lysis by denaturing immunoprecipitation.. (B) Quantification of (A). (C) GFP 
cleavage from SZ*-GFP was assayed in wild-type and doa10Δ yeast as described in Figure 20. (D) Wild-
type, doa10Δ, and ydj1Δ yeast expressing SZ*-GFP were examined by fluorescent microscopy. Both the 
full length species and the cleaved GFP are shown; CMAC staining marks the vacuole and DIC is shown. 
(E) Quantification of GFP intensity in the vacuole in part (D) was determined from >100 cells in each 
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strain; Statistical significance was determined with a one-way ANOVA and Dunn’s multiple comparison 
tests.  ** p<0.005, *** p<0.0005. (F) The GFP cleavage rate of SZ*-GFP was measured in a pulse chase 
assay in wild-type and doa10Δ yeast. The cleavage rate was determined by normalizing cleaved GFP to 
full-length SZ*-GFP at 0 min, and the relative GFP cleavage rate in doa10Δ yeast at 60 min was 
standardized to 100%. (G) An in vitro budding assay was performed with microsomes prepared from 
wild-type and doa10Δ yeast expressing SZ*. T: 10% total protein; -: budded proteins in a reaction without 
COPII proteins; +: budded proteins in a reaction with COPII proteins. (H) Microsomes from wild-type 
and doa10Δ expressing SZ* were incubated at 26°C or 37°C for 30 min, and treated with 1% dodecyl 
maltoside (DDM) for 30 min on ice. Protein residing in the supernatant (S) and pellet (P) fractions was 
analyzed after centrifugation at 18,000g for 30 min. Data represents means ± SE of three independent 
experiments. 
 
To confirm this result, I next performed an in vitro budding assay to directly measure the 
efficiency of SZ* ER export. Consistent with the in vivo data shown above, deleting DOA10 
resulted in a higher SZ* budding efficiency when microsomes from wild-type and doa10 cells 
were examined (Figure 22G). Finally, to assess if substrate aggregation also contributed to ER 
retention, the DDM solubility of SZ* was tested in lysates prepared form these strain 
backgrounds. As shown in Figure 22H, DDM solubility was unchanged, regardless of whether 
Doa10 was present. Therefore, the loss of Doa10 has no effect on SZ* solubility yet still affects 
ER retention. Overall, these data demonstrated that ubiquitination, but not necessarily 
aggregation, can act as a hallmark for ER retention.   
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3.3.5  The addition of four tandem ubiquitins prevents SZ* exit from the ER 
To confirm my hypothesis that ubiquitin is sufficient to retain an ERAD substrate in the 
ER, I surmised that attachment of a poly-ubiquitin tag to SZ* will be sufficient to prevent ER 
export. To this end, I first constructed a chimeric substrate, SZ*-Ub4, with four tandem 
ubiquitins attached to the C-terminus of SZ*-GFP (Figure 23A). In these constructs, the K48 and 
K63 positions in the appended ubiquitin moieties were mutated to R to minimize the formation 
of a poly-ubiquitin chain on the ubiquitin tag. Furthermore, these four ubiquitins were 
constructed in a head-to-tail fashion, which lead to poor targeting of a cytosolic protein to the 
ubiquitin-proteasome pathway (Zhao and Ulrich, 2010).  
I first tested if attachment of four ubiquitins changed the degradation pathway. Similar to 
SZ*, SZ*-Ub4  was also sorted into the vacuole for degradation through the MVB pathway 
(Figure 23B; note the cleaved GFP signal, top panel in wild-type and vps36Δ yeast). Moreover, 
the amount of cleaved GFP from SZ*-Ub4 was much lower than the amount of cleaved GFP 
form SZ*-GFP (compare lane 1 and 5). These results strongly suggest that the ubiquitin motif 
prevents ER exit. Since the ubiquitin motif was attached to the C-terminus of GFP, the epitope in 
GFP in the full-length protein (but not the cleaved GFP) was obscured by ubiquitin, as the full-
length band signal enhanced by boiling the nitrocellulose membrane (data not shown). To 
confirm these results, cells expressing SZ*-Ub4 were examined by fluorescence microscopy. 
Consistent with measurements of GFP cleavage by immunoblot (Figure 23B), imaging data 
showed decreased vacuolar GFP intensity (i.e., the population that exited the ER) of SZ*-Ub4 
compared to SZ*-GFP (Figure 23C and 23D). The level of GFP cleavage from SZ*-Ub4 also 
remained similar regardless whether Doa10 was present (Figure 23B and 23D). To confirm that 
the presence of a poly-ubiquitin motif was sufficient to prevent ER exit, I then performed an in 
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vitro budding assay to test the efficiency of SZ*-Ub4 exit from the ER. In contrast to the efficient 
budding of SZ*-GFP in the microsomes prepared from the doa10Δ strain, SZ*-Ub4 failed to exit 
the ER, even in the absence of Doa10 (Figure 23E) (compare lane 6 and 12). These data 
demonstrate both in vivo and in vitro that a four-tandem ubiquitin motif prevents ER export of a 
misfolded protein that is targeted for both ERAD and post-ERQC.  
A K11 poly-ubiquitin linkage was found to be enriched in ERAD substrates (Locke et al., 
2014). Because K11 is still present in the four-tandem ubiquitin tag—and therefore could have 
acquired a poly-ubiquitin linkage—I next tested if the tag induces poly-ubiquitination on SZ*-
Ub4. However, poly-ubiquitination could not be detected on SZ*-Ub4 in either DOA10 or 
doa10Δ cells (Figure 23F). In contrast, SZ*-GFP was poly-ubiquitinated in DOA10 cells, as 
anticipated (Figure 23G). These data preclude the possibility that the four-tandem ubiquitin 




Figure 23 Four tandem ubiquitin prevent SZ* from entering COPII vesicles 
 (A) Predicted topology of GFP-tagged SZ* and SZ*-Ub4. (B) GFP cleavage of SZ*-GFP and SZ*-Ub4 
in the wild-type and indicated mutant strains was determined when cell lysates were examined with anti-
GFP (to detect the cleaved GFP) and anti-HA (to detect the full length species) by immunoblotting. (C) 
Wild-type and doa10Δ yeast expressing SZ*-Ub4 were examined by fluorescent microscopy. Both the 
full length species and the cleaved GFP are shown; CMAC staining marks the vacuole and DIC is shown. 
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(D) Quantification of GFP intensity in the vacuole in part (C). More than 100 cells in each strain were 
counted; Statistical significance was determined with a one-way ANOVA and Dunn’s multiple 
comparison tests. *** p<0.0005. (E) In vitro budding efficiency was measured in a budding assay using 
microsomes prepared from wild-type and doa10Δ cells expressing SZ*-GFP or SZ*-Ub4. T: 10% total 
protein; -: budded proteins in a reaction without COPII proteins; +: budded proteins in a reaction with 
COPII proteins. (F) The ubiquitination of SZ*-Ub4 was detected in cell lysates after by denaturing 
immunoprecipitation in wild-type, hrd1Δ and doa10Δ yeast. (G) The ubiquitination of SZ*-GFP was 
similarly detected as in (F) in wild-type, hrd1Δ and doa10Δ cells. 
3.4  DISCUSSION  
Most proteins transported to post-ER compartments are concentrated in COPII vesicles 
by interacting with cargo receptors, such as members of the Erv complex and Sec24 family 
members (Gomez-Navarro and Miller, 2016). In order to be recognized by COPII cargo 
receptors, many transport competent proteins have to present an ER exit signal. In many cases, 
the presentation of a functional ER exit signal seems to be tightly coupled with protein folding, 
as misfolded proteins are mostly excluded from COPII vesicles and retained in the ER for 
proteasome degradation (Ma et al., 2017). However, this view has been challenged by a growing 
number of misfolded proteins that exit the ER through COPII-mediated anterograde trafficking 
and are targeted either for vacuolar degradation or for proteasome degradation after retrieval 
from later compartments. Nevertheless, other misfolded proteins may still present an ER exit 
signal, but due to the robust nature of the ERAD pathway, these substrates are prevented from 
leaving the ER. In this chapter, I sought to understand how a misfolded protein, SZ*, that 
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contains both an ERAD-C degron as well as an ER exit signal, can be retained in the ER and 
destroyed by the ERAD pathway. 
My earlier work established that the aggregation of SZ* contributed to ER retention and 
directed the substrate to the ERAD pathway versus ER exit (Sun and Brodsky, 2018). However, 
aggregation is most likely not a common feature for ER retention, indicating that ERAD employs 
other mechanisms to compete with the COPII machinery to retain substrates. To this end, I first 
examined which step in the ERAD pathway regulates ER export. During this effort, factors 
required for substrate recognition and ubiquitination were tested.  
Ydj1 is a type I Hsp40 that regulates the function of Hsp70 (Kampinga and Craig, 2010). 
It directly captures its substrate and delivers them to Hsp70 for refolding or ubiquitination (Cyr 
et al., 1992; Kampinga and Craig, 2010; Lu and Cyr, 1998; Nakatsukasa et al., 2008). I first 
inhibited the substrate recognition step of SZ* ERAD by deleting YDJ1. Surprisingly, SZ* was 
more efficiently routed for vacuolar degradation upon YDJ1 deletion. This provided the first 
evidence suggesting that loss of Ydj1 promotes ER export of an ERAD substrate. With the 
robust ER exit of SZ* in vivo as shown by the cycloheximide chase data and imaging data, an 
efficient in vitro budding efficiency was expected. However, the in vitro budding of SZ* in wild-
type yeast could not be detected compared to the positive control Erv46. As shown in chapter 2 
and chapter 3, SZ* is subject to both ERAD and COPII-mediated ER export, which together 
determines the fate of SZ*: ERAD versus post-ER degradation. However, the in vitro budding 
assay contains only the minimum components required for less efficient COPII budding but all 
the ER retention factors in the microsomes, thereby shifting the competition more for ER 
retention. Even for ERAD-L substrate, CPY*, which undergoes constant ER export before 
ERAD, the in vitro budding efficiency is as low as 1% (Vashist et al., 2001). Considering the 
 104 
difference between ERAD-C and ERAD-L branches and the competition between ERAD and ER 
export of SZ*, the undetectable ER budding in vitro is not surprising.   
Thus far, Ydj1 has only been shown to slow the degradation of ER-retained misfolded 
proteins (Guerriero et al., 2017; Huyer et al., 2004b; Sun and Brodsky, 2018; Youker et al., 
2004). As might be expected, the loss of Ydj1 also decreased SZ* detergent solubility, which at 
first might seem to contradict the fact that the loss of Ydj facilitates its ER export. However, it is 
worth mentioning that substrate aggregation induced by either heat-stress or overexpression, as 
described in the previous chapter, has no effect on substrate ubiquitination. Also, substrate 
aggregation induced by the deletion of YDJ1 may be less severe than that induced by heat-stress 
or overexpression. More pertinent, however, the loss of Ydj1 obviated substrate ubiquitination. 
To more definitively parse the contributions of aggregation and ubiquitination, I next 
focused on the ERAD-C-specific E3 ubiquitin ligase, Doa10. Deletion of DOA10 enhanced ER 
export of SZ*. This observation is reminiscent of a previous study reporting that inactivation of 
ERAD by deleting ERAD-L E3 ligase, Hrd1, promoted ER exit of an ERAD-L substrate, CPY* 
(Kincaid and Cooper, 2007). Most importantly, the detergent solubility of SZ* remains 
unchanged regardless of whether Doa10 was present. This experiment allowed me to uncouple 
the dual effects caused by YDJ1 knockout: increased substrate insolubility and decreased 
substrate ubiquitination. Therefore, inhibiting substrate ubiquitination by either directly deleting 
the E3 ligase or indirectly via the loss of a chaperone promotes ER export of ERAD substrate. 
Together, poly-ubiquitin can act as a hallmark for ER retention. To definitively support this 
conclusion, SZ* was fused to four-tandem ubiquitin tag at its C-terminus. A four-tandem 
ubiquitin motif was previously shown to be sufficient for targeting cytosolic proteins for 
proteasome degradation, albeit with a poor efficiency (Zhao and Ulrich, 2010). With its head-to-
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tail conformation, which resembles the K63 ubiquitin linkage (Komander et al., 2009), the four 
tandem ubiquitin fusion may not target SZ* for efficient ERAD since K63 is not a favorable 
ERAD signal (Grice and Nathan, 2016; Locke et al., 2014). However, this provides an advantage 
as this motif confers ER retention but inefficient degradation (Zhao and Ulrich, 2010). As 
predicted, SZ*-Ub4 was retained in the ER and less was directed to the vacuole compared to 
SZ*-GFP. Also, SZ*-GFP was more stable when fused to Ub4. Of note, SZ*-Ub4 forms puncta 
in the ER, which is reminiscent of the pattern seen when other misfolded proteins formed ER-
associated compartments (ERACs) (Huyer et al., 2004a; Kakoi et al., 2013). One of these 
substrates is CFTR, which when expressed in yeast forms ERACs that co-localize with COPII 
components, including Sar1, Sec13 and Sec23. Considering that SZ*-GFP can enter COPII for 
ER export, it is very likely that the puncta formed by SZ*-Ub4 resulted from ERAC formation. 
In the future, this can be studied by co-localization experiments with SZ*-Ub4 and COPII 
components.  
To better accommodate the rate-limiting step of retrotranslocation, ERAD needs to 
efficiently and rapidly recognize and ubiquitinate substrates, which once ubiquitinated are then 
retained in the ER and retrotranslocated. The mechanism of ER retention of ubiquitinated 
substrates may result from both active retention by multiple ubiquitin-binding proteins in the ER, 
such as the Cdc48 cofactors Ufd1 and Npl4, or by passive retention by excluding poly-
ubiquitinated substrates that either have their ER exit signals obscured by poly-ubiquitination or 
are simply too large to enter the COPII vesicles. The identification of putative ER-retention 
ubiquitin-binding factors in the ER will also be investigated in the near future. 
In summary, by inhibiting a pre-ubiquitination step in the ERAD pathway, i.e., substrate 
recognition or ubiquitination, I demonstrated that substrate ubiquitination can dictate ER 
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retention. Furthermore, I identified the ER-associated Hsp40, Ydj1, as a gatekeeper for ERAD 
substrates as its deletion allows a misfolded protein to escape the ER and its overexpression 
enhanced ERAD. I also provide the first evidence that a four tandem-ubiquitin motif is sufficient 





4.0  CONCLUSIONS AND FUTURE DIRECTIONS 
In this chapter, I will summarize my work and describe how they advance the scientific 
understanding of ERAD in terms of substrate selection. Both short-term and long-term 
experiments are proposed to provide some intellectual insights to future directions.  
4.1  CONCLUSIONS 
My project began with a simple question: why do some misfolded proteins exit the ER 
before being degraded while others are statically retained in the ER? To address this question, I 
set out to understand the features in a misfolded substrate that dictates its fate for ERAD versus 
post-ER degradation.  
The scrutiny of misfolded proteins that exit the ER before degradation revealed that these 
substrates bear folding lesions in either the lumenal domain or in the transmembrane domain. 
Therefore, I first sought to investigate if a substrate with a ERAD-C degron has the potential to 
be exported from the ER. Before my study, no known substrates bearing cytosolic folding lesions 
were shown to leave the ER. I thus designed a novel substrate, SZ*, that stems from a post-
ERQC substrate, Wsc1*, but with its wild-type cytosolic domain replaced with a canonical 
cytosolic degron (NBD2*) (Wang and Ng, 2010). To simplify the substrate and minimize the 
potential for ER retention mediated by ERAD-L factors, the lumenal domain of Wsc1* was also 
replaced with a triple-HA tag, which allowed for protein detection. As predicted, the cytosolic 
degron, NBD2*, drove SZ* to the conventional ERAD-C pathway, which requires Hsp40 
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(Ydj1), Hsp70 (Ssa1), an E3 ligase (Doa10), Cdc48, which extracts proteins from the ER, and 
the proteasome (Sun and Brodsky, 2018). Surprisingly, inhibiting ERAD by inactivating these 
factors only partially stabilized SZ*, with more than half still being degraded. This indicated the 
involvement of another degradation pathway during clearance of SZ*: transport to the vacuole. 
Given the multiple routes that direct proteins from the ER to the vacuole, I first tested if ER-
phagy is responsible for sorting SZ* to the vacuole. By testing the degradation of SZ* in 
multiple mutants defective in autophagy, the ER-phagy pathway was ruled out as none of those 
mutants stabilized SZ*. These results suggested that SZ* was degraded in the vacuole via the 
post-ERQC pathway. Dissection of the post-ER degradation requirements for SZ* demonstrated 
that SZ* advances to the Golgi through COPII-mediated forward trafficking and is then directly 
sorted to the vacuole by way of the MVB pathway.  
To date, most substrates are exclusively eliminated by only one PQC machinery. 
Vacuole/lysosome -targeted GQC substrates such as Wsc1* and Pep12(D) lack an ERAD 
determinant, which makes them ERAD resistant. In contrast, most canonical ERAD substrates, 
due to a dominant ERAD signal that overrides an ER exit signal if otherwise exposed, are 
efficiently degraded by ERAD under normal conditions (Spear and Ng, 2003; Wolf and Schafer, 
2005). SZ* thus serves as the first substrate that can be selected for degradation by both the 
ERAD and post-ERQC pathways, which also provided a powerful tool for studying the 
competition between ERAD and post-ERQC.  In addition, my data demonstrated that substrates 
with cytosolic folding lesions still have the potential for ER export, which argues against the idea 
that ERAD-C substrates are all retained in the ER (Vashist et al., 2001).  
Protein aggregation has been implicated as the cause for multiple human diseases, such as 
Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease (Aguzzi and O'Connor, 
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2010; Ross and Poirier, 2004; Valastyan and Lindquist, 2014). Hydrophobic motifs that may lead 
to protein aggregation if improperly positioned were previously shown to be an ERAD signal for 
a cytosolic protein, serum- and glucocorticoid-induced kinase 1 (Sgk1) (Arteaga et al., 2006). It 
is worth mentioning that Sgk1 associates tightly with ER membrane so that it employs the 
ERAD machinery for its degradation. Deletion or reduction of hydrophobicity redistributed Sgk1 
to the nucleus and cytosol. These studies indicated that protein aggregation may acts as an 
ERAD targeting signal. To test this hypothesis, I applied a variety of stressors to yeast cells 
expressing SZ*, and its ERAD dependence was assayed. Based on those data, I demonstrated 
that protein aggregation induced by heat-stress enhanced ERAD targeting of SZ*. Next, I sought 
to induce the aggregation of SZ* without a temperature shift. The homology model of the degron 
in NBD2* suggested that this truncation makes the domain aggregation prone (Preston et al., 
2018). Therefore, I overexpressed SZ* to drive aggregation. As expected, SZ* became less 
soluble in detergent when overexpressed, thereby increasing ERAD targeting. Together with the 
data described above, I was able to demonstrate that substrate aggregation dictates the fate of 
SZ* for ERAD over post-ER degradation (Sun and Brodsky, 2018). Meanwhile, a similar 
construct, ChiA*, which bears two transmembrane segment but with the same cytosolic degron, 
NBD2*, was constructed by Dr. Chris Guerriero (Guerriero et al., 2017). Although ChiA* was 
targeted exclusively for ERAD, results with multiple truncation variants of ChiA* revealed a 
positive correlation between ERAD degradation rate and substrate aggregation propensity, 
suggesting that ERAD favors aggregation prone substrates (Preston et al., 2018).  
My conclusions could be explained by the following mechanisms: (1) Substrate 
aggregation may induce rapid ERAD of SZ* by more efficient recognition by the ERAD 
machinery, and degradation occurred so rapidly there was no time for ER export; (2) Substrate 
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aggregation may obscure the ER exit signal, which makes this poorly exported substrate an even 
lower efficient post-ERQC substrate; (3) Substrate aggregation may make the protein physically 
too large to enter COPII vesicles. In line with my conclusion, our lab recently reported that 
protein aggregation can direct a substrate for the ERAD pathway. In this parallel study, detergent 
insolubility of a series of ERAD substrates appeared to be negatively correlated with protein 
half-life (Preston et al., 2018). Therefore, my data provided the first evidence showing that 
substrate aggregation may assist ERAD to win the battle against post-ERQC.  
My next question was, “how might ERAD substrates be rescued for ER export?” To 
answer this question, I decided to investigate the ER export of SZ* by inhibiting individual steps 
during ERAD. Previous studies have shown that disabling ERAD by deleting an ERAD-specific 
E3 ligase could result in enhanced ER export of some ERAD substrates that display a functional 
ER exit signal (Kincaid and Cooper, 2007). This, nevertheless, raises more questions than 
answers for the mechanism behind this phenomenon remained unclear and only one step in the 
ERAD pathway (Hrd1-medited ubiquitination) was inhibited.  
I first demonstrated that inhibiting the ERAD recognition step by deleting Hsp40 YDJ1 
resulted in more efficient ER export of SZ*. Ydj1 was also shown as a gatekeeper for ERAD as 
its overexpression lead to increased ER retention of SZ*, and deletion increased ER exit. By 
constructing an Ydj1-HPD mutant that is defective for substrate ubiquitination, I was able to 
show that its ability to retain SZ* in the ER was mediated by substrate ubiquitination and 
potentially aggregation, and that Hsp70 function was also required for this process. I next 
inactivated the ERAD-C-specific E3 ligase DOA10. Similar to the YDJ1 deletion, SZ* more 
efficiently exited the ER both in vivo and in vitro upon loss of Doa10. These data suggested 
further that substrate ubiquitination is necessary for ER retention, particularly because substrate 
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aggregation was unaffected in the doa10∆ strain. To test if ubiquitin was sufficient to mediate 
substrate ER retention independent of the ubiquitination machinery, four-tandem ubiquitins were 
attached covalently to the C-terminus of SZ*. Surprisingly, the ER exit of SZ*-Ub4, as indicated 
by the presence of cleaved GFP after vacuolar delivery, was negligible compared to SZ*. Even 
in the absence of Doa10, SZ*-Ub4 remained mostly in the ER with little being delivered to the 
vacuole, suggesting that ubiquitin is sufficient for retaining SZ*. These studies showed for the 
first time that ubiquitin acts as a hallmark that is necessary and sufficient for ER retention, 
thereby providing insights into how to rescue membrane proteins from ERAD by targeting the 
steps prior to substrate ubiquitination. This could serve as a promising therapeutic strategy for 
some human diseases such as lysosomal storage diseases. Lysosomal storage diseases are caused 
by mutations in lysosomal enzymes that result in protein misfolding and the subsequent 
degradation by ERAD (Platt et al., 2018). Some mutations disturb protein stability but still 
maintain partial function if rescued for lysosomal transport (Grace et al., 1994; Hruska et al., 
2008). ER export rescue by inhibiting substrate ubiquitination may thus be beneficial in 
facilitating lysosomal transport of these misfolded enzymes especially glucocerebrosidase. In 
terms of the mutant plasma membrane proteins such as CFTR, ER export rescue may not be 
sufficient to protect proteins en route to the plasma membrane. Therefore, a combination of 
ERAD inhibition and other pharmacologic correctors are both required to correct mutant CFTR 
(Brodsky and Frizzell, 2015; Chung et al., 2016). 
In summary, my work in this thesis sought to address two questions: (1) Are misfolded 
proteins with ERAD-C degrons able to exit the ER for post-ER degradation? (2) What features 
of misfolded proteins dictate their fate for ERAD versus post-ER degradation? By rational 
alteration of a post-ERQC substrate with a canonical ERAD-C degron, Wsc1*, I designed a 
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novel model substrate, SZ*, that is degraded by both ERAD and post-ER degradation. My 
further investigation with SZ* provided the first mechanistic evidence that substrate aggregation 
and ubiquitination can favor ERAD over post-ER degradation.  
4.2  FUTURE DIRECTIONS 
In light of my discoveries, it is important to highlight several limitations as well. Such 
considerations will further guide future work toward pursuing a detailed mechanism of substrate 
ER retention and ERAD.  
First, does inhibition of post-ubiquitination steps of ERAD, including Cdc48-mediated 
retrotranslocation and proteasomal degradation, promote ER export of SZ*? My work only 
focused on substrate recognition and ubiquitination. For example, in mammalian cells, inhibiting 
a post-ubiquitination step of ERAD, such as retrotranslocation, promotes ER export of misfolded 
lysosomal glucocerebrosidase (GC), which is linked to lysosomal storage disorders (Wang et al., 
2011a). It is worth noting that inhibition of retrotranslocation with the small molecule 
eeyarestatin I (Eer I) caused significant induction of the UPR and apoptosis, suggesting that the 
increased ER export of GC probably resulted from an indirect effect of the UPR, which promotes 
both protein folding and ER export (Travers et al., 2000; Wang et al., 2011a). In contrast, only 
treatment with kifunensine, which inhibits ER mannosidase I during the ERAD recognition step, 
rescued ER export of mutant GC without inducing the UPR and apoptosis. Additional studies are 
thus needed to determine if inhibiting a post-ubiquitination step during ERAD directly rescues 
substrate ER export. To this end, a temperature sensitive Cdc48 mutant, cdc48-3, will be used to 
inhibit retrotranslocation without causing significant ER stress compared to EerI treatment. 
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Pulse-chase assays will be conducted to monitor SZ*-GFP cleaved in both the CDC48 and 
cdc48-3 background when Cdc48 is functional or non-functional, respectively. Concurrently, the 
ER exit of SZ* will be directly measured in an in vitro budding assay using SZ*-containing 
microsomes from both CDC48 and cdc48-3 strains. Next, the proteasomal degradation step of 
ERAD will be inhibited by treatment of yeast lacking the multidrug pump, Pdr5, with the 
proteasome inhibitor MG132. Both the pulse-chase assay and in vitro budding assay will again 
be performed upon addition of MG132 or the vehicle, DMSO. I hypothesize that inhibiting a 
post-ubiquitination step of ERAD (by either inactivating Cdc48 or adding the proteasome 
inhibitor) will fail to rescue ER export of SZ*.  Together with my current study, I will be able to 
provide the first evidence that pre-ubiquitination steps are key targets for promoting the ER exit 
of misfolded proteins.  
Second, how do four tandem ubiquitins drive SZ* puncta formation? Are the puncta 
formed by SZ*-Ub4 ERAC? Appending four tandem ubiquitins dramatically changed the 
localization of SZ* from a mostly vacuolar location to puncta that seem to reside at the ER 
(Figure 22D and Figure 23C). However, further characterization of the puncta formed by SZ*-
Ub4 is needed. These puncta are reminiscent of ERAC structures formed by CFTR (expressed in 
yeast) and other misfolded membrane proteins like Ste6-L1239X (Huyer et al., 2004a; Kakoi et 
al., 2013). CFTR, when expressed in yeast, sequesters in ERACs that co-localize with COPII 
components, including Sar1 and Sec23 (Kakoi et al., 2013). Since SZ* still bears a functional ER 
exit signal that can efficiently drive more than half of SZ* for ER exit, I hypothesize that four 
tandem ubiquitins target SZ* for sequestration into ERACs that co-localize with COPII 
components. To this end, an ER-localized fluorescent protein, Sec63-mCherry, will be used to 
confirm the ER localization of SZ*-Ub4. The co-localization between SZ*-Ub4 and COPII 
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components, including Sar1, Sec23, and Sec24, will be then tested. A previous study has shown 
that ERAC formation of CFTR requires the Hsp40s, Ydj1 and Hlj1, although their functions 
during this process remain unknown. Based on my hypothesis that ubiquitin drives SZ* to enter 
ERACs, the four-tandem ubiquitin attachment should bypass the requirement for Hsp40 (Ydj1 in 
this case) during ERAC formation by SZ*. To test this hypothesis, the localization pattern of 
SZ*-Ub4 will be imaged in both wild-type and ydj1Δ strains. To further expand the significance 
of my work, other wild-type proteins that efficiently exit the ER such, as the plasma membrane 
protein Yor1, will be used to test if four-tandem ubiquitins is sufficient to drive ERAC 
formation. Yor1 is the yeast ortholog of CFTR, and also has been modeled at a site (ΔF670) 
orthologous to the most common cystic fibrosis causing mutant ΔF508 (Katzmann et al., 1999; 
Louie et al., 2012). Therefore, Yor1 will be a valuable substrate to test my hypothesis, since the 
results may be applicable to CFTR due to the overall homology between Yor1 and CFTR. These 
experiments will advance our understanding of how ERACs are formed, I propose that ubiquitin 
may act as the driving force to sequester substrates into ERACs. 
Third, what factors in the ER mediate ER retention of a ubiquitinated substrate? ER-
localized ubiquitin binding proteins are the main candidates because ubiquitin binding domains 
(UBDs) on those proteins can selectively bind ubiquitin (Hicke and Dunn, 2003; Husnjak and 
Dikic, 2012). There are about 80 proteins in yeast that contain UBDs, many of which are 
associated with the ER (Tsuchiya et al., 2017). In the long term, a fluorescent imaging-based 
screen could be used to identify specific UBD-containing proteins that mediate ER retention of 
SZ*-Ub4. In this screen, ERAC formation of SZ*-Ub4 will be imaged in yeast lacking individual 
genes that encode UBD-containing proteins. The loss of ERAC formation of SZ*-Ub4, and its 
accumulation in the vacuole, will implicate a specific UBD-containing protein. Because the four-
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tandem ubiquitin motif is not an ERAD-favored ubiquitin linkage, one can also perform the in 
vitro budding assay with SZ*-Ub4 and then titrate potential ubiquitin binding proteins away with 
increasing concentrations of purified K48 linked tetra-ubiquitin. Based on my hypothesis, the in 
vitro addition of K48 tetra-ubiquitin may outcompete the linear ubiquitin on SZ* for binding to a 
UBD-containing protein that mediates ER retention, which will be indicated by increased 
packaging of SZ*-Ub4 into COPII vesicles in vitro.  
Fourth, can de-ubiquitination rescue the ER export of misfolded substrate when ERAD is 
functional? ERAD activity is tightly modulated in cells, because both hyperactive and 
hypoactive ERAD can wreak havoc on protein homeostasis and even cause cell death (Guerriero 
and Brodsky, 2012; Hebert and Molinari, 2007). My study mostly spotlighted how ERAD 
modulation affects ER export of misfolded proteins. With the discovery that substrate 
ubiquitination acts as an ER retention signal, it will be intriguing to investigate in the future if 
de-ubiquitination of the substrate rescues ER export. This will shed light on the targeted rescue 
of misfolded protein without modulating ERAD activity. To this end, SZ* will be fused to the 
catalytic domain of a non-specific DUB from herpes virus that has been shown to render the 
protein to which it is attached non-ubiquitinable (Stringer and Piper, 2011). The strong de-
ubiquitination function of DUB is further evidenced by a recent study where a DUB confers 
dominant-negative effects even to a ubiquitin ligase when fused to the enzyme (MacDonald et 
al., 2017). As a control, a catalytically dead mutant of DUB will be fused to the protein of 
interest. Both the in vivo GFP cleavage assay and an in vitro budding assay will be performed to 
test ER export efficiency in the presence of active or inactive DUB. Based on my discovery, I 
hypothesize that the appended DUB will facilitate ER export of SZ*.  
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To further expand the significance of my study, it is necessary to test how ubiquitination 
and de-ubiquitination affect ER export of native yeast proteins that localize in a post-ER 
compartment, such as the plasma membrane. Yor1 seems to be a good candidate because: (1) It 
is a plasma membrane protein that requires ER export; (2) The levels of Yor1 that reach the 
plasma membrane can be tested by oligomycin resistance on a yeast spot assay; (3) The 
Yor1ΔF670 mutant is mostly trapped in the ER and is eliminated by ERAD; (4) Yor1 is a CFTR 
homolog that is natively expressed in yeast. Therefore, the DUB will be fused to both wild-type 
Yor1 and Yor1ΔF670 mutant. The catalytically inactive DUB will be used as a control. Besides 
the GFP cleavage and in vitro budding assay used above, the oligomycin resistant spot assay will 
be conducted to investigate the physiological relevance of my findings. If the DUB fusion 
enhances ER export and oligomycin resistance of Yor1 and the mutant, these experiments will 
shed light on the significance of rescuing the ER export of misfolded proteins by modulating 





YEAST STRAINS, PLASMIDS, AND PRIMERS USED IN THIS STUDY 
Table 1 Yeast strains used in this study 
Strain Genotype Reference 
BY4742  MATα, his3Δ1, leu2Δ0, lys2Δ0 ura3Δ3 (Winzeler et al., 1999) 
pdr5Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 pdr5Δ::KanMX (Winzeler et al., 1999) 
pdr5Δ 
pep4Δ 
MATα, met15Δ0, his3Δ1, leu2Δ0, ura3Δ3 
pdr5Δ::KanMX, pep4Δ::KanMX 
This lab 
vps4Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 vps4Δ::KanMX (Winzeler et al., 1999) 
vps23Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 vps23Δ::KanMX (Winzeler et al., 1999) 
vps36Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 vps36Δ::KanMX (Winzeler et al., 1999) 
vps27Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 vps27Δ::KanMX (Winzeler et al., 1999) 
snf7Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 snf7Δ::KanMX (Winzeler et al., 1999) 
atg1Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 atg1Δ::KanMX (Winzeler et al., 1999) 
atg5Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 atg5Δ::KanMX (Winzeler et al., 1999) 
atg8Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 atg8Δ::KanMX (Winzeler et al., 1999) 
atg9Δ MATα, his3Δ1, leu2Δ0, ura3Δ3atg9Δ::KanMX (Winzeler et al., 1999) 
atg11Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 atg11Δ::KanMX (Winzeler et al., 1999) 
SSA1 MATα, his3-11,15, leu2-3,112, ura3-52. trp1-Δ1, lys2, 
ssa2- 1(LEU2), ssa3-1(TRP1), ssa4-2(LYS2)  
(Becker et al., 1996) 
ssa1-45 MATα, his3-11,15, leu2-3,112, ura3-52. trp1-Δ1, lys2, 
ssa1-45, ssa2-1(LEU2), ssa3-1(TRP1), ssa4-2(LYS2)  
(Becker et al., 1996) 
KAR2 MATa ura3-52, leu2-3,112, ade2-101 (Sanders et al., 1992) 
kar2-1 MATa, kar2-1, ura3-52, leu2-3,112, ade2-101 (Brodsky et al., 1999) 
HLJ1 YDJ1 MATα, ade2, his3, leu2, ura3, trp1 (Youker et al., 2004) 
 ydj1-151 MATα, ade2, his3, leu2 ,ura3, trp1, can1-100, ydj1-
2::HIS3 ydj1-151::LEU2 
(Youker et al., 2004) 
DOA10 
HRD1 
MATa, his3-Δ200, leu2-3,112, ura3-52, lys2-801, trp1-
1, gal2 
(Huyer et al., 2004b) 
doa10Δ MATa,  his3-Δ200, leu2-3,112, ura3-52, lys2-801, trp1-
1, gal2, doa10Δ::HIS3 
(Huyer et al., 2004b) 
hrd1Δ MATa, his3-Δ200, leu2-3,112, ura3-52, lys2-801, trp1-
1, gal2, hrd1Δ::LEU2 
(Huyer et al., 2004b) 
doa10Δ MATa, his3-Δ200, leu2-3,112, ura3-52, lys2-801, trp1- (Huyer et al., 2004b) 
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hrd1Δ 1, gal2 doa10Δ::HIS3, hrd1Δ::LEU2 
cdc48-2 Back-crossed 3X to BY4742 (Moir et al., 1982) 
W303-1A MATa, ura3-1, his-3-11,15, ade2-1, trp1-1, leu2-3,112 
and can1-100 
(Wallis et al., 1989) 
RSY300  MATa his3-11,15 leu2-3,112 ura3-1 se7-4 (Lupashin et al., 1996) 
CBY616  MATa his3Δ200 ura3-52 leu2Δ1 trp1Δ63 Charles Barlowe lab 
CBY829 MATa his3Δ200 ura3-52 leu2Δ1 trp1Δ63 ypt1-3 (Otte et al., 2001) 
CBY1060 MATa his3Δ200 ura3-52 leu2Δ1 trp1Δ63 sec23-1 Charles Barlowe lab 
CBY1703  MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 sec18-1 isogenic to 
BY4742 
Charles Barlowe lab 
ydj1Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 ydj1Δ::KanMX (Winzeler et al., 1999) 
hlj1Δ MATα, his3Δ1, leu2Δ0, ura3Δ3 hlj1Δ::KanMX (Winzeler et al., 1999)  
CBY1285 Used for Sec23/Sec24 purification Charles Barlowe lab 
CBY120 Used for Sec13/Sec31 purification Charles Barlowe lab 
 
Table 2 Yeast plasmids used in this study 
Plasmids Description Reference 
pSZ01 CEN URA3 P-TEF  SZ* This study 
pSZ02 CEN URA3 P-TEF  SZ This study 
pSZ03 CEN URA3 P-TEF  SZ*-GFP This study 
pSZ04 CEN URA3 P-TEF  W-N This study 
pSZ05 CEN URA3 P-TEF  W-N* This study 
pSZ06 CEN URA3 P-TEF  3HA-NBD2* This study 
pSZ07 2µ URA3 P-TEF  3HA-NBD2* This study 
pSZ08 2µ URA3 P-TEF  SZ* This study 
pSW148 CEN LEU2 P-GAS  Wsc1*  (Prasad et al., 2012) 




CaURA3 CEN URA3 P-TEF  sfGFP (Lee et al., 2013) 
pHSE-lacZ 2µ URA3 P-SSA3  LacZ (Santoro et al., 1998) 
pYEP96 2µ TRP1 hsf1-R206S (Sewell et al., 1995) 
pCG01 2µ URA3 ste6–166NBD2 
(Guerriero et al., 
2013) 
pSZ09 
CEN URA3 P-TEF  SZ*-GFP with BamHI site between 
GGGGS linker and GFP  mutated and subcloned with 
XbaI/BamHI sites This study 
pSZ10 CEN URA3 P-TEF  SZ*-GFP-Ub4 This study 
pSZ11 CEN LEU2 P-Ydj1  Ydj1 Elizabeth Craig lab 
pSZ12 CEN URA3 P-Ydj1  Ydj1-QAA This study 
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Ydj1* 
(BPM569) CEN URA3 P-Ydj1  CEN URA3 P-Ydj1  Ydj1-PY/GG (Fang et al., 2014) 
CBB205 Used for Sar1 purification (Barlowe et al., 1994) 
 
Table 3 Primers used in this study 
Primer Sequence (5'-3') Reference 




ctcagtgcaagaaagccaatgtaggg This study 
OSZ03 aagaaagccaatgtaggggc This study 
OSZ04 agtactcgagttattcactatgcgttataaccattgttag This study 
OSZ05 gcaaaaacctttattattcaatggaaccatcag This study 
OSZ06 gttatctctgatggttccattgaataat This study 
OSZ07 agtactcgagttaactgctttggttggaaacaatttg This study 
OSZ08 gtactctagaatgtttttcaacagactaag This study 
OSZ09 
gtacggatcctgagccacctcctcctgagcctccaccaccagatccacccccc
cctctgacaatcaacaagatataaagagcaatg This study 
OSZ10 
gtcaatccagacgaagctgatgccatggcctacccatacgatgttcctgactat
gcgggc This study 
OSZ11 
gcccgcatagtcaggaacatcgtatgggtaggccatggcatcagcttcgtctg
gattgac This study 
OSZ12 gtcaactagtatgagaccgaacaaaacaag This study 
OSZ13 gtacactagtatgtacccatacgatgttcctg This study 
OSZ14 gcctttagacatggagcctgagccacctcct This study 
OSZ15 aggaggtggctcaggctccatgtctaaaggc This study 
OSZ16 gtcaggatccctttgtacaattcgtccattc This study 
OSZ17 agcttcctcacttggattcttagctgcttggtattttaaggcgcattttc This study 
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